NO180484B - Fremgangsmåte for fremstilling av substituerte piperidiner - Google Patents
Fremgangsmåte for fremstilling av substituerte piperidiner Download PDFInfo
- Publication number
- NO180484B NO180484B NO933413A NO933413A NO180484B NO 180484 B NO180484 B NO 180484B NO 933413 A NO933413 A NO 933413A NO 933413 A NO933413 A NO 933413A NO 180484 B NO180484 B NO 180484B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- found
- compound
- alkyl
- nmr
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 150000003053 piperidines Chemical class 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000003638 chemical reducing agent Substances 0.000 claims description 10
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 150000002466 imines Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000002274 desiccant Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000012458 free base Substances 0.000 description 45
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 150000003840 hydrochlorides Chemical class 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 235000011121 sodium hydroxide Nutrition 0.000 description 8
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 102100024304 Protachykinin-1 Human genes 0.000 description 6
- 101800003906 Substance P Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GFMAFYNUQDLPBP-QWRGUYRKSA-N (2s,3s)-2-phenylpiperidin-3-amine Chemical compound N[C@H]1CCCN[C@H]1C1=CC=CC=C1 GFMAFYNUQDLPBP-QWRGUYRKSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000003141 Tachykinin Human genes 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 108060008037 tachykinin Proteins 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical class O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- AFUKNJHPZAVHGQ-UHFFFAOYSA-N 2,5-dimethoxy-Benzaldehyde Chemical compound COC1=CC=C(OC)C(C=O)=C1 AFUKNJHPZAVHGQ-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 description 1
- XTHJCITVHCRQRD-UHFFFAOYSA-N 2-phenylpyridin-3-amine Chemical compound NC1=CC=CN=C1C1=CC=CC=C1 XTHJCITVHCRQRD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 241000871311 Toxicodendron vernix Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- QDUXDCXILAPLAG-UHFFFAOYSA-N hydron;1-methylpiperidine;chloride Chemical compound Cl.CN1CCCCC1 QDUXDCXILAPLAG-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FBDWCTWJJMORIU-UHFFFAOYSA-N magnesium;hexahydrate Chemical compound O.O.O.O.O.O.[Mg] FBDWCTWJJMORIU-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical class NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002455 vasospastic effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
- C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
- C07C45/513—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an etherified hydroxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Bakgrunn for oppfinnelsen
Foreliggende oppfinnelse angår nye fremgangsmåter for stereoselektiv fremstilling av substituerte piperidin-derivater .
De substituerte piperidinene og beslektede forbindelser som kan fremstilles ved fremgangsmåtene ifølge oppfinnelsen,
er substans P-reseptor-antagonister og er derfor nyttige for behandling av sykdommer mediert ved et overskudd av substans P.
Substans P er et naturlig forekommende undekapeptid som hører til tachykinin-familien av peptider, idet de sistnevnte betegnes slik på grunn av deres raskt stimulerende virkning på glattmuskel-vev. Mer spesifikt er substans P et farmakolo-gisk aktivt neuropeptid som produseres i pattedyr (idet det opprinnelig ble isolert fra tarmen) og har en karakteristisk aminosyresekvens som er illustrert av D. F. Veber et al. i US-patent 4.680.283.
Den utstrakte innvirkning substans P og andre tachy-kininer har på patofysiologien for en rekke sykdommer er godt demonstrert innen teknikken. F.eks. er substans P vist å være innblandet ved transmisjon av smerte eller migrene (se B.E.B. Sandberg et al., Journal of Medicinal Chemistry,
vol. 25, s. 1009 (1982)), så vel som ved sentralnervesystem-forstyrrelser så som angst og schizofreni, ved respiratoriske og inflammatoriske sykdommer så som henholdsvis astma og reumatoid artritt, ved reumatiske sykdommer så som fibrositt og ved gastrointestinale lidelser og sykdommer i GI-trakten, så som ulcerøs kolitt og Crohns sykdom etc. (se D. Regoli i "Trends in Cluster Headache", ed. F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, 1987, s. 85-95).
Flere av de substituerte pyridinene og beslektede forbindelser som kan fremstilles ved fremgangsmåtene ifølge foreliggende oppfinnelse, er beskrevet i PCT patentsøknad PCT/US90/00116, innlevert 4. januar 1990, US-patentsøknad 07/717.943, innlevert 20. juni 1991 og US-patentsøknad 07/724.268, med tittelen "3-Aminopiperidine Derivatives and Related Nitrogen Containing Heterocycles", innlevert 1. juli 1991, som alle er overdratt som foreliggende søknad. Andre fremgangsmåter for fremstilling av slike forbindelser er angitt i en US-patentsøknad med tittelen "Preparation of Substituted Piperidines", som ble innlevert 27. november 1991 og er overdratt som foreliggende søknad.
Oppsummering av oppfinnelsen
Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av en forbindelse med formelen
hvor
R3 er H eller -CH^R1, R<1> er aryl valgt fra indanyl, fenyl og naftyl; heteroaryl valgt fra tienyl, furyl, pyridyl og kino-lyl; og cykloalkyl med 3 til 7 karbonatomer, hvor et av karbonatomene eventuelt kan være erstattet av nitrogen, oksy-gen eller svovel; hvor hver av aryl- og heteroaryl-gruppene eventuelt kan være substituert med én eller flere substituenter, og (C3.7) -cyklo-alkylgruppen eventuelt kan være substituert med én eller to substituenter, idet substituentene uavhengig er valgt fra klor, fluor, brom, jod, nitro, (Ci-io)alkyl eventuelt substituert med fra én til tre fluor-grupper, (C^o) alkoksy eventuelt substituert med fra én til tre fluor-grupper, amino, i^.^) alkyl-S-, (C^o) alkyl-SO- , (d.10) alkyl-S02-, fenyl, fenoksy, { C^ o) alkyl-S02NH- , (d-xo) alkyl-S02NH- ( C^) alkyl- , (C^o) alkylamino-di-(Ci-10) alkyl-, cyano, hydroksy, cykloalkoksy med 3 til 7 karbonatomer, (Ci.g) alkylamino, ((^.g) dialkylamino, HCONH- og (C^) - alkyl-CO-NH-, hvor nitrogena tomene i amino- og (C^g) alkylamino -gruppene eventuelt kan være beskyttet med en passende beskyttelsesgruppe,- og R2 er tienyl, benzhydryl, naftyl eller fenyl eventuelt substituert med fra én til tre substituenter uavhengig valgt fra klor, brom, fluor, jod, cykloalkoksy med 3 til 7 karbonatomer, (C^o) alkyl eventuelt substituert med fra én til tre f luor-grupper og (C^o) alkoksy eventuelt substituert med fra én til tre fluorgrupper, med det forbehold, når R<3> er
-CHj-R<1>, at enten er R<1> substituert med minst én av (Cx.10) alkyl substituert med én eller flere fluorgrupper eller (C^o)alkoksy substituert med fra én til tre fluorgrupper, eller R2 er substituert med minst én eller flere fluorgrupper, eller (ci-io) alkoksy substituert med fra én til tre f luorgrupper, som omfatter reduksjon av en forbindelse med formelen
hvor R<2> er som angitt ovenfor, for å danne en forbindelse med formel I' hvor R<3> = H, dvs. en forbindelse med formelen
hvor R<2> er som angitt ovenfor,
og hvis man ønsker en forbindelse med formel I' hvor R<3> er -CHj-R<1>, omsetning av forbindelsen (IV) med enten (a) en for-bin-delse med formelen R<1>COX, hvor R<1> er som angitt ovenfor og X er en utgående gruppe, fulgt av behandling av det resulterende amid med et reduksjonsmiddel, (b) en forbindelse med formelen R<1>CHO, hvor R<1> er som angitt ovenfor, i nærvær av et
reduksjonsmiddel, (c) en forbindelse med formelen R<1>CH2X/ hvor R<1> er som angitt ovenfor og X er en utgående gruppe, eller (d) en forbindelse med formelen R^HO, hvor R<1> er som angitt ovenfor, i nasrvær av et tørremiddel eller ved anvendelse av et
apparat som azeotropt fjerner det dannede vann, for å fremstille et imin med formelen
hvor Ri og R2 er som angitt ovenfor, og omsetning av iminet med et reduksjonsmiddel, fortrinnsvis natrium-triacetoksybor-hydrid.
Forbindelsene med formel I har chirale sentere og kan derfor eksistere i forskjellige enatiomere former. Formel I, som angitt ovenfor, omfatter alle optiske isomerer av slike forbindelser og blandinger derav.
Detaljert beskrivelse av oppfinnelsen
Fremgangsmåtene og produktene ifølge foreliggende oppfinnelse er illustrert i det følgende reaksjonsskjerna. Bortsett fra hvis annet er angitt, er formlene I, II og IV og substituentene R<1>, R<2> og X som angitt ovenfor i reaksjonsskjemaet og beskrivelsen som følger.
Omsetningen av en forbindelse med formel IV med en forbindelse med formelen R^CHO for å danne en forbindelse med formel I utføres typisk i nærvær av et reduksjonsmiddel så som natriumcyanoborhydrid, natriumtriacetoksyborhydrid, natrium-borhydrid, hydrogen og en metallkatalysator, sink og saltsyre eller maursyre, ved en temperatur fra ca. -60°C til ca. 50°C. Egnede reaksjons-inerte oppløsningsmidler for denne omsetningen omfatter lavere alkoholer (f.eks. metanol, etanol og isopropanol), eddiksyre og tetrahydrofuran (THF). Fortrinnsvis er oppløsningsmidlet eddiksyre, temperaturen er ca. 25°C og reduksjonsmidlet er natriumtriacetoksyborhydrid. Denne reaksjonen gir et materiale hvor tilsetningen av CH^-side-kjeden skjer selektivt ved 3-aminogruppen, og isomeren med formel I er det eneste produktet som isoleres.
Alternativt kan omsetningen av en forbindelse med formel IV med en forbindelse med formelen I^CHO utføres i nærvær av et tørremiddel eller under anvendelse av et apparat som azeotropt fjerner det dannede vann, for å danne et imin med formelen
som derefter omsettes med et reduksjonsmiddel som beskrevet ovenfor, fortrinnsvis med natriumtriacetoksyborhydrid ved ca. romtemperatur. Fremstilling av iminet utføres vanligvis i et reaksjonsinert oppløsningsmiddel så som benzen, xylen eller toluen, fortrinnsvis toluen, ved en temperatur fra ca. 25°C til ca. 110°C, fortrinnsvis ved ca. oppløsningsmidlets til-bakeløpstemperatur. Egnede tørrmidler/oppløsningsmiddel-systemer omfatter titantetraklorid/diklormetan, titan-isopropoksyd/diklormetan og molekylsikt/THF. Titantetra-klorid/diklormetan er foretrukket.
Omsetningen av en forbindelse med formel IV med en forbindelse med formelen I^CHjX utføres typisk i et reaksjonsinert oppløsningsmiddel så som diklormetan eller THF, fortrinnsvis diklormetan, ved en temperatur fra ca. 0°C til ca. 60°C, fortrinnsvis ved ca. 25°C.
Omsetningen av en forbindelse med formel IV med en forbindelse med formelen I^COX utføres typisk i et inert opp-løsningsmiddel så som tetrahydrofuran (THF) eller diklormetan ved en temperatur fra ca. -20°C til ca. 60°C, fortrinnsvis i diklormetan ved ca. 0°C. Reduksjon av det resulterende amid oppnås ved behandling med et reduksjonsmiddel så som boran-dimetylsulfid-kompleks, litiumaluminiumhydrid eller diisobutylaluminiumhydrid i et inert oppløsningsmiddel så som etyleter eller THF. Reaksjonstemperaturen kan være i området fra ca. 0°C til ca. tilbakeløpstemperaturen til oppløsnings-midlet. Fortrinnsvis utføres reduksjonen under anvendelse av boran-dimetylsulfid-kompleks i THF ved ca. 60°C.
Reduksjon av pyridinet med formel II for å danne det tilsvarende piperidin med formel IV utføres vanligvis under anvendelse av enten natrium i alkohol, litiumaluminiumhydrid/- aluminiumtriklorid, elektrolytisk reduksjon eller hydrogen i nærvær av en metall-holdig katalysator. Reduksjon med natrium utføres vanligvis i en kokende alkohol, fortrinnsvis butanol, ved en temperatur fra ca. 20°C til ca. tilbakeløpstemperaturen til oppløsningsmidlet, fortrinnsvis ved ca. 120°C. Reduksjonen med litiumaluminiumhydrid/aluminiumtriklorid utføres vanligvis i eter, THF eller dimetoksyetan, fortrinnsvis eter, ved en temperatur fra ca. 25°C til ca. 100°C, fortrinnsvis ved ca. romtemperatur. Den elektrolytiske reduksjonen utføres fortrinnsvis ved romtemperatur, men temperaturer fra ca. 10°C til ca. 60°C er også egnet.
Hydrogenering i nærvær av en metallholdig katalysator er den foretrukne reduksjonsmetode. Egnede hydrogenerings-kata-lysatorer omfatter palladium, platina, nikkel, platinaoksyd og rhodium. Den foretrukne katalysator for hydrogeneringen er platina på karbon. Reaksjonstemperaturen kan være i området fra ca. 10°C til ca. 50°C, idet ca. 25°C er foretrukket. Hydrogeneringen utføres vanligvis ved et trykk fra ca. 1,5 til ca. 4 atmosfærer, fortrinnsvis ved ca. 3,0 atmosfærer, i et egnet inert oppløsningsmiddel så som eddiksyre eller en lavere alkohol, fortrinnsvis metanol, med omtrent en støkiometrisk mengde av hydrogenklorid tilstede. Når reduksjonen utføres ved hydrogenering i nærvær av en metall-holdig katalysator, isoleres bare materiale med cis-konfigurasjon, og pyridin-ringen reduseres selektivt i motsetning til 2-fenyl-gruppen.
Utgangsmaterialene med formlene R^OX, R<1>CH0 og R<1>CH2X som anvendes ved ovenstående reaksjoner, er enten kommersielt tilgjengelige eller kan oppnås ved utførelse av standard omdannelser som er velkjent for fagfolk på området fra kommersielt tilgjengelige materialer.
I alle de ovenstående reaksjoner hvor et piperidinderivat omdannes til et annet piperidin-derivat (dvs. IV -» I), opp-rettholdes den absolutte stereokjemi ved karbonatomene i 2- og 3-stillingene i piperidin-ringen. Ved hver slik reaksjon kan en racemisk blanding eller en ren enantiomer derfor oppnås ved å anvende det passende utgangsmateriale med den samme stereo-k j emi.
Spaltning av en racemisk blanding av en forbindelse med formel I for å fremstille (+)-enantiomeren av en slik forbindelse utføres vanligvis under anvendelse av metanol, etanol eller isopropanol, fortrinnsvis isopropanol, som det organiske, reaksjonsinerte oppløsningsmiddel. Fortrinnsvis utføres spaltningen ved å blande en racemisk blanding av en forbindelse med formel I og (R)-(-)-mandelsyre i isopropanol, og omrøre blandingen for å danne et utfelt, optisk anriket mandelsyre-salt. Det optisk anrikede utfelte stoff omkrystalliseres derefter to ganger fra isopropanol, hvorefter det omkrystal-liserte presipitat omdannes til den frie base av den optisk rene forbindelsen med formel I ved fordeling mellom diklormetan og en vandig base så som natriumhydroksyd, natrium-bikarbonat eller kaliumbikarbonat, fortrinnsvis natriumhydroksyd, eller ved omrøring av en alkoholisk oppløsning av saltet med en basisk ionebytterharpiks. Den frie basen, som oppløses i metylenklorid, kan derefter omdannes til det tilsvarende salt av saltsyre. Isolering av mandelatet kan utfø-res ved temperaturer fra ca. 0°C til ca. 40°C. Ca. 25°C er foretrukket.
I alle de ovenfor beskrevne eller illustrerte reaksjoner er trykket ikke kritisk hvis ikke annet er angitt. Trykk fra ca. 0,5 atmosfærer til ca. 5,0 atmosfærer er vanligvis godtagbare, og omgivelsestrykk, dvs. ca. 1 atmosfære, er foretrukket av praktiske grunner.
Forbindelsene med formel I og deres farmasøytisk godtagbare salter oppviser substans P reseptor antagonist-aktivitet og er derfor verdifulle for behandling og forhindring av en rekke kliniske lidelser hvor behandling eller forhindring utføres eller lettes ved reduksjon av substans P mediert neurotransmisjon. Slike lidelser omfatter inflammatoriske sykdommer (f.eks. artritt, psoriasis, astma og inflammatoriske tarmsykdommer), angst, depresjon eller dysthymiske forstyrrel-ser, kolitt, psykose, smerte, allergier så som eksem og rinitt, kronisk obstruktiv luftveis-sykdom, hyper-sensitivitets-lidelser så som ved giftsumak, vasospastiske sykdommer så som angina, migrene og Reynauds sykdom, fibrose-og kollagen-sykdommer så som skleroderma og eosinofil fascioliase, refleks-sympatetisk dystrofi så som skulder/hånd-syndrom, tilvennings-lidelser så som alkoholisme, stress-relaterte somatiske lidelser, perifer neuropati, neuralgi, neuropatologiske lidelser så som Alzheimers sykdom, AIDS-relatert demens, diabetisk neuropati og multippel sklerose, lidelser forbundet med immun-forsterkning eller suppresjon så som systemisk lupus erytematose og reumatiske sykdommer så som fibrositt. Disse forbindelsene tilpasses således for terapeu-tisk anvendelse som substans P reseptor antagonister for kontroll og/eller behandling av hvilke som helst av de ovenfor angitte kliniske lidelser hos pattedyr, innbefattet mennesker.
Forbindelsene med formel I og de farmasøytisk godtagbare salter derav kan administreres enten via oral, parenteral eller topisk administreringsvei. Vanligvis administreres
disse forbindelsene fortrinnsvis i doser i området fra ca. 5,0 mg opp til ca. 1500 mg pr. dag, selv om variasjoner nødvendig-vis vil forekomme avhengig av vekten og tilstanden til indivi-det som behandles og den spesielle administreringsvei som
velges. Imidlertid anvendes fortrinnsvis et dosenivå i området ca. 0,07 mg til ca. 21 mg pr. kg kroppsvekt pr. dag.
De følgende eksempler illustrerer fremgangsmåtene og forbindelsene ifølge foreliggende oppfinnelse, men begrenser ikke omfanget derav.
Som angitt ovenfor, er utgangsmaterialene anvendt ved fremgangsmåtene ifølge oppfinnelsen enten kommersielt tilgjengelige eller kan oppnås ved utførelse av standard omdannelser som er velkjent for fagfolk på området, fra kommersielt tilgjengelige materialer. Tabell 1 nedenfor angir hvordan aldehydene med formelen R^-CHO anvendt i eksemplene ble oppnådd. Standard omdannelsene anvendt for å fremstille disse aldehydene er angitt ved én eller flere små bokstaver i kolon-nen betegnet "Reaksjonssekvens" i Tabell 1. Bokstavene anvendt for å angi slike omdannelser er angitt i forklaringen efter Tabell l.
<*> Reagenser for f rems til liner av R^ HO ved standard metoder
a) Cl2CHOCH3, TiCl4
b) - dimetylsulf at
c) Br2/HOAc
d) cyklopentylbromid
e) metyljodid
f) acetylklorid
g) NaOCH2CF3
h) Raney-nikkel, HC02H
i) Se02
j) 1) karbonyldiimidazol, 2) N,O-dimetylhydroksylamin,
3) diisobutylaluminiumhydrid
k) BBr3
1) t-butylklorid/AlCl3
m) C12CH0CH3/A1C13
n) etyljodid
p) C1F2CH
q) isopropylbromid
r) H2, Pd/C, HCHO
s) 1) metanol/HCl, 2) metylsulfonylklorid, 3) metyljodid,
4) diisobutylaluminiumhydrid, 5) Mn02
t) boran-metylsulfid kompleks
u) monoperoksyftalsyre, magnesiumsalt-heksahydrat v) H2-Pd/BaS04
Eksempel 1
(+)-( 2S, 3S)- 3- amino- 2- fenylpiperidin
I en kolbe ble plassert 9 g 10% palladium-karbon, 180 ml metanol, 275 ml etanol, 6,5 ml konsentrert saltsyre og 9 g av hydrokloridsaltet av (2S,3S)-3-(2-metoksybenzylamino)-2-fenylpiperidin. Blandingen ble rystet under hydrogen (2,8 kg/cm<2>) natten over, 9 g ytterligere katalysator ble satt til systemet, og blandingen ble rystet under hydrogen i 1 dag. Blandingen ble fortynnet med vann (250 ml), filtrert gjennom diatoméjord (celite (varemerke)), og celiten ble skyllet godt med vann. Filtratet ble konsentrert til et volum på ca. 600-700 ml, gjort basisk med konsentrert, vandig natriumhydroksyd og ekstrahert med kloroform, og kloroformekstraktene ble tørret (natriumsulfat) og konsentrert for å få 4,4 g av tittelforbindelsen som en farveløs olje.
[o;]D (HCl-salt) = +62,8° (c = 0,46, metanol (CH3OH) .
<l>H NMR (CDC13) 5 1,68 (m, 4H) , 2,72 (m, 1H) , 2,94 (bred s, 1H) , 3,16 (m, 1H), 3,80 (d, 1H, J=3), 7,24 (m, 5H).
HRMS beregnet for CX1H16N2: 176,1310, funnet: 176,1309. Beregnet for CX1H16N2 • 2HC1 • 1/3H20: C 51,78; H 7,36; N 10,98 Funnet: C 51,46; H 7,27; N 10,77
Eksempel 2
( + )-( 2S. 3S) - 3-( 2. 5- dimetoksybenzylamino)- 2- fenylpiperidin
I en rundbunnet kolbe ble under en nitrogenatmosfære plassert 600 mg (3,4 mmol) (+)-(2S,3S)-3-amino-2-fenylpiperidin, 8 ml eddiksyre og 622 mg (3,7 mmol) 2,5-dimetoksy-benzaldehyd, og blandingen ble omrørt i 30 minutter. Til systemet ble satt 1,58 g (7,5 mmol) natriumtriacetoksyborhydrid, og blandingen ble omrørt ved romtemperatur natten over. Blandingen ble konsentrert, gjort basisk med IM vandig natriumhydroksyd og ekstrahert med metylenklorid. Metylenklorid-ekstraktene ble vasket med vann og ekstrahert med IM vandig saltsyre. Saltsyre-ekstraktene ble gjort basiske med IM vandig natriumhydroksyd og ekstrahert med metylenklorid. Metylenklorid-ekstraktene ble tørret (natriumsulfat) og konsentrert for å få 528 mg av en farveløs olje. Oljen ble oppløst i metylenklorid, og eter mettet med hydrogenklorid ble satt til oppløsningen. Det resulterende, hvite faste stoff ble oppsamlet ved filtrering og omrørt i isopropanol ved 60°C i 2 timer. Filtrering ga 414 mg av tittelforbindelsen i form av hydrokloridet. Ytterligere materiale (400 mg) ble oppnådd ved ekstraksjon av det opprin-nelige basiske lag med ytterligere metylenklorid, tørring (natriumsulfat) og konsentrasjon.
[a]D (HCl-salt) = +60,5° (c = 0,58, CH30H).
<1>H NMR (CDC13) 6 1,38 (m, 1H) , 1,58 (m, 1H) , 1,88 (m, 1H) , 2,13 (m, 1H), 2,78 (m, 2H), 3,25 (m, 1H), 3,36 (d, 1H, J=18), 3,44 (s, 3H), 3,62 (d, 1H, J=18), 3,72 (s, 3H), 3,88 (d, 1H, J=3), 6, 62 (m, 3H), 7,24 (m, 5H) .
Masse-spektrum: m/z 326 (moder).
Beregnet for C20H26N202 • 2HC1 • 0 , 25H20 : C 59,48; H 7,11; N 6,93 Funnet: C 59,33; H 6,91; N 7,23
Eksempel 3
Cis- 3- amino- 2 - fenylpiperidin
I en kolbe ble plassert 2,65 g (15,6 mmol) 3-amino-2-fenylpyridin, 10,6 g 5% platina/karbon og 106 ml 1,5M HC1 i metanol. Blandingen ble rystet under en atmosfære (ca. 2,8 kg/cm<2>) av hydrogen i 2,5 timer. Vann ble satt til systemet, blandingen ble filtrert gjennom en pute av diatoméjord, og puten ble skyllet med ca. 700 ml vann. Filtratet ble gjort basisk med fast natriumhydroksyd og ekstrahert med to porsjo-ner av diklormetan. De samlede organiske fraksjoner ble vasket med vann, tørret (natriumsulfat) og konsentrert med en rotasjonsinndamper for å få 2,4 g av tittelforbindelsen som en gul olje.
Beregnet for C1:U16N20 • 0,25H20: C 73,08; H 9,20; N 15,89. Funnet: C 72,80; H 9,46; N 15,84
Tittelforbindelsene i Eksemplene 4-23 og 25-81 ble frem-stilt fra enten (+)-(2S,3S)-3-amino-2-fenylpiperidin eller det tilsvarende racemat ved anvendelse av det passende aldehyd og en fremgangsmåte lik den som er beskrevet i Eksempel 2.
Eksempel 4
Cis- 3-( 4. 5- difluor- 2- metoksvbenzylamino)- 2- fenylpiperidin
aH NMR (CDC13) 5 1,30 (irt, 1H) , 1,62 (m, 2H) , 1,96 (m, 1H) , 2,68 (m, 2H), 3,18 (m, 2H), 3,32 (s, 3H), 3,44 (d, 1H, J=14), 3,82 (d, 1H, J=3) , 6,38 (dd, 1H, J=6,12), 6,66. (dd, 1H, J=8, 10), 7,16 (m, 5H).
HRMS beregnet for C19H22N2F20: 332,1697. Funnet: 332,1698 Beregnet for C19H22N2OF2 • 2HC1 • 0, 85H20: C 54,25; H 6,15; N 6,66 Funnet: C 54,26; H 5,84; N 6,94
Eksempel 5
Cis- 3-( 2- klor- 4- fluorbenzylamino)- 2- fenylpiperidin
<X>H NMR (CDCI3) 6 1,44 (m, 1H) , 2,06 (m, 1H) , 2,78 (m, 2H) , 3,24 (m, 1H), 3,40 (d, 1H, J=12), 3,58 (d, 1H, J=12), 3,88 (d, 1H, J=3), 6,75 (m, 1H), 6,92 (m, 2H), 7,26 (m, 5H).
HRMS beregnet for C18H20N2<35>C1F: 318,1294. Funnet: 318,1280.
Eksempel 6
Cis- 3-( 2- etoksybenzylamino)- 2- fenylpiperidin
<X>H NMR (CDCI3) 3 1,10 (t, 3H, J=5), 1,40 (m, 1H) , 1,62 (m, 1H) , 1,90 (m, 1H), 2,14 (m, 1H), 2,80 (m, 2H), 3,27 (m, 1H), 3,38 (d, 1H, J=15), 3,69 (m, 3H), 3,86 (d, 1H, J=2), 6,64 (d, 1H, J=8) , 6,78 (t, 1H, J=6), 6,94 (d, 1H, J=6), 7,12 (t, 1H, J=8), 7,24 (m, 5H).
HRMS beregnet for C20H26N2O: 310,2041. Funnet: 310,2045.
Eksempel 7
Cis- 3-( 2- hydroksybenzylamino)- 2- fenylpiperidin
<X>H NMR (CDCI3) 6 1,62 (m, 3H) , 2,10 (m, 1H) , 2,79 (m, 1H) , 2,92 (m, 1H), 3,20 (m, 1H), 3,48 (s, 2H), 3,82 (d, 1H, J=2), 6,72 (m, 3H), 7,08 (m, 1H), 7,36 (m, 5H).
HRMS Beregnet for C18H22N20: 282,1732. Funnet: 282,1724 Beregnet for C18H22N20• 2HC1 • 2H20: C 55,26; H 7,20; N 7,16 Funnet: C 55,13; H 7,12; N 6,84
Eksempel 8
Cis- 3-( 3, 5- difluor- 2- metoksybenzylamino)- 2- fenylpiperidin
<X>H NMR (CDCI3) a 1,45 (m, 1H) , 1,64 (m, 1H) , 1,86 (m, 1H) , 2,08 (m, 1H), 2,80 (m, 2H), 3,24 (m, 1H), 3,44 (d, 1H, J=15), 3,54 (d, 1H, J=15) , 3,68 (s, 3H) , 3,90 (d, 1H, J=3) , 6,57 (dd, 1H, J=8, 9), 6,69 (dd, 1H, J=9, 12), 7,28 (m, 5H).
HRMS Beregnet for C19H22N2OF2: 332,1698. Funnet: 332,1700 Beregnet for C19H22N20F2 • 2HC1: C 56,30; H 5,97; N 6,92 Funnet: C 56,17; H 5,84; N 6,59
Eksempel 9
Cis- 3-( 2- klor- 6- fluorbenzylamino)- 2- fenylpiperidin
<X>H NMR (CDCI3) a 1,40 (m, 1H) , 1,66 (m, 1H) , 1,90 (m, 1H) , 2,15 (m, 1H), 2,78 (m, 2H), 3,26 (m, 1H) , 3,68 (d, 2H, J=18), 3,72 (d, 1H, J=18), 6,82 (m, 1H), 7,04 (m, 2H), 7,22 (m, 5H).
HRMS beregnet for C18H20N2ClF-2HCl-2/3H2O:
C 53,56; H 5,83; N 6,95
funnet: C 53,63; H 5,53; N 6,83
Eksempel 10
( 2S. 3S)- 3-( 5- klor- 2- metoksybenzylamino)- 2- fenylpiperidin Sm.p. 275-277°C (HCl-salt).
<:>H NMR (CDCI3) 3 1,40 (m, 1H) , 1,60 (m, 1H) , 1,90 (m, 1H) , 2,08 (m, 1H), 2,79 (m, 2H), 3,26 (m, 1H), 3,36 (d, 1H, J=15), 3,45
(S, 3H), 3,60 (d, 1H, J=15), 3,88 (d, 1H, J=3), 6,56 (d, 1H, J=8), 6,92 (d, 1H, J=3), 7,06 (dd, 1H, J=3, 8), 7,28 (m, 5H). Massespektrum: m/z 330 (moder).
Eksempel 11
Cis- 3-( 5- klor- 2- metoksYbenzylamino)- 2- fenylpiperidin
'H NMR (CDC13) 6 1,37 (m, 1H) , 1,56 (m, 1H) , 1,86 (m, 1H) , 2,06 (m, 1H), 2,76 (m, 2H), 3,23 (m, 1H), 3,32 (d, 1H, J=15), 3,42 (S, 3H), 3,58 (d, 1H, J=15), 3,85 (d, 1H, J=3), 6,54 (d, 1H, J=8), 6,90 (d, 1H, J=3), 7,04 (dd, 1H, J=3, 8), 7,24 (m, 5H).
Eksempel 12
Cis- 3-( 2. 5- dimetoksybenzylamino)- 2- fenylpiperidin
Sm.p. 250-252°C (HCl-salt).
<1>H NMR (CDCI3) 6 1,28-1,40 (m, 1H) , 1,48-1,92 (m, 2H), 2,02-2,14 (m, 1H), 2,66-2,80 (m, 2H), 3,14-3,24 (m, 1H), 3,32 (d, 1H, J=18), 3,38 (s, 3H), 3,56 (d, 1H, J=18) , 3,66 (s, 3H) , 3,83 (d, 1H, J=3), 6,48-6,62 (m, 3H) , 7,10-7,26 (m, 5H) .
HRMS beregnet for C20H26N202: 326,1995. Funnet: 326,1959 Analyse for C20H26N2O2 • 2HC1 • 0, 3H20:
Beregnet: C 59,34; H 7,12; N 6,92
Funnet: C 59,33; H 6,96; N 6,76
Eksempel 13
Cis- 3-( 5- fluor- 2- metoksybenzylamino)- 2- fenylpiperidin
Sm.p. 270-272°C (HCl-salt).
HRMS Beregnet for C19H23FN20: 314,1791. Funnet: 314,1766. Analyse for C19H23FN20 • 2HC1 • 0 , 5H20 :
Beregnet: C 57,58; H 6,61; N 7,07
Funnet: C 57,35; H 6,36; N 7,03
<1>H NMR (CDCI3) 6 1,30-1,42 (m, 1H) , 1,48-2,12 (m, 3H) , 2,64-2,82 (m, 2H), 3,12-3,26 (m, 1H), 3,32 (d, 1H, J=12), 3,42 (s, 3H), 3,56 (d, 1H, J=12), 3,84 (d, 1H, J=3), 6,53 (dd, 1H, J=5, 10), 6,64 (dd, 1H, J=3, 8), 6,70-6,80 (m, 1H), 7,12-7,40 (m, 5H) .
Eksempel 14
Cis- 2- fenyl- 3-[ 2-( prop- 2- yloksy) benzylamino1piperidin
'H NMR (CDC13) 6 1,00 (m, 6H) , 1,30 (m, 1H) , 1,70 (m, 2H) , 2,10 (m, 1H), 2,72 (m, 2H), 3,18 (m, 1H), 3,30 (m, 1H), 3,50 (m, 1H), 3,80 (br s, 1H), 4,06 (m, 1H), 6,66 (m, 2H), 6,90 (m, 1H), 7,05 (m, 1H), 7,20 (m, 5H).
HRMS Beregnet for C21H28N20: 324,2197. Funnet: 324,2180 Beregnet for C21H2eN20 • 2HC1 • 1, 66H20: C 59,02 ? H 7,85; N 6,55 Funnet: C 59,07; H 7,77; N 6,69
Eksempel 15
Cis- 3-( 3- fluor- 2- metoksybenzylamino)- 2- fenylpiperidin
<X>H NMR (CDCI3) 6 1,40 (m, 1H) , 1,60 (m, 1H) , 1,86 (m, 1H) , 2,08 (m, 1H), 2,80 (m, 2H), 3,23 (m, 1H), 3,36 (m, 1H), 3,58 (m, 4H), 3,88 (m, 1H), 6,80 (m, 3H), 7,26 (m, 5H).
HRMS Beregnet for C19H23FN20: 314,1794. Funnet: 314,1768. Beregnet for C19H23FN20 • 2HC1 • 1, 5H20 : C 55,08; H 6,80; N 6,76 Funnet: C 54,89; H 6,48; N 6,79
Eksempel 16
Cis- 3- ( 5- klor- 3- f luor- 2- metoksybenzylamino) - 2- fenylpiperidin <X>H NMR (CDC13) 6 1,42 (m, 1H) , 1,54 (m, 1H) , 1,80 (m, 1H) , 2,06 (m, 1H), 2,78 (m, 2H), 3,20 (m, 1H), 3,42 (d, 1H, J=15), 3,58 (d, 1H, J=15), 3,64 (s, 3H), 3,86 (m, 1H), 6,66 (d, 1H, J=9), 6,91 (d, 1H, J=9), 7,26 (m, 5H).
HRMS Beregnet for C19H22FN20C1: 348,1401. Funnet: 348,1406.
Eksempel 17
Cis- 3-( 3- klor- 5- fluor- 2- metoksybenzylamino)- 2- fenylpiperidin <l>H NMR (CDCI3) 6 1,44 (m, 1H) , 1,58 (m, 1H) , 1,80 (m, 1H) , 2,06 (m, 1H), 2,80 (m, 2H), 3,22 (m, 1H), 3,42 (d, 1H, J=18), 3,54 (d, 1H, J=18), 3,66 (s, 3H), 3,88 (d, 1H, J=2), 6,55 (d, 1H, J=6), 6,92 (d, 1H, J=9), 7,26 (m, 5H).
HRMS Beregnet for C19H22C1FN20: 348,1401. Funnet: 348,1411 Beregnet for C19H22C1FN20 • 2HC1 • 0 , 25H20: C 53,53; H 5,79; N 6,57 Funnet: C 53,58; H 5,60; N 6,41
Eksempel 18
Cis- 3-( 3, 5- diklor- 2- metoksybenzylamino)- 2- fenylpiperidin
'H NMR (CDCI3) 6 1,44 (m, 1H) , 1,56 (m, 1H) , 1,82 (m, 1H) , 2,08 (m, 1H), 2,80 (m, 2H), 3,20 (m, 1H), 3,50 (m, 2H), 3,64 (s, 3H), 3,88 (m, 1H), 6,68 (s, 1H), 7,26 (m, 6H).
HRMS Beregnet for C19H22C12N20: 364,1105. Funnet: 364,1105. Beregnet for C19H22C12N20• 2HC1: C 52,07; H 5,52; N 6,39
Funnet: C 51,69; H 5,50; N 6,32.
Eksempel 19
Cis- 3-( 4- metoksybenzylamino)- 2- fenylpiperidin
Sm.p. 264-266°C (HCl-salt).
<X>H NMR (CDCI3) a 1,28-1,40 (m, 1H) , 1,44-1,88 (m, 2H) , 1,92-2,02 (m, 1H), 2,64-2,84 (m, 2H), 3,10-3,22 • (m, 1H), 3,19 (d, 1H, J=12), 3,39 (d, 1H, J=12), 3,70 (s, 3H), 3,81 (d, 1H, J=3), 6,65 (d, 2H, J=8), 6,83 (d, 2H, J=6), 7,12-7,28 (m, 5H). HRMS Beregnet for C19H24N20: 296,1885. Funnet: 296,1871 Beregnet for C19H24N20 • 2HC1 • 0 , 6H20: C 60,03; H 7,21; N 7,37 Funnet: C 60,08; H 7,11; N 7,45
Eksempel 20
Cis- 2- fenvl- 3 -( tien- 2- ylmetylamino) piperidin
Sm.p. 250-252°C (HCl-salt) .
<*>H NMR (CDC13) 5 1,30-1,40 (m, 1H) , 1,46-1,52 (m, 1H) , 1,68--1,86 (m, 1H), 1,92-2,00 (m, 1H), 2,64-2,78 (m, 1H), 2,84-2,92 (m, 1H), 3,12-3,22 (m, 1H), 3,44 (d, 1H, J=12), 3,54 (d, 1H, J=12), 3,81 (d, 1H, J=3), 6,53 (d, 1H, J=4), 6,72-6,80 (m, 1H) , 7,02 (d, 1H, J=6) , 7,12-7,30 (m, 5H) .
HRMS Beregnet for C16H20N2S: 272,1373. Funnet: 272,1327. Beregnet for C16H20N2S • 2HC1 • 1, 1H20 : C 52,62; H 6,67; N 7,67 Funnet: C 52,64; H 6,38; N 7,65
Eksempel 21
Cis- 3-( 2- metoksynaft- l- ylmetylamino)- 2- fenylpiperidin
Sm.p. 222-225°C (HCl-salt).
<l>H NMR (CDC13) 5 1,36-1,48 (m, 1H) , 1,52-2,04 (m, 2H) , 2,18-2,32 (m, 1H), 2,68-2,82 (m, 1H), 2,90 (d, 1H, J=3), 3,18-3,28 (m, 1H), 3,64 (s, 3H), 3,80 (d, 1H, J=12), 3,86 (d, 1H, J=4), 4,07 (d, 1H, J=12), 7,02-7,32 (m, 8H), 7,57 (d, 1H, J=8) , 7,60-7,70 (m, 2H).
HRMS Beregnet for C23H26N20: 346,2041. Funnet: 346,2043.
Eksempel 22
Cis- 2- fenyl- 3-( tien- 3- ylmetylamino) piperidin
Sm.p. 264-267°C (HCl-salt).
'H NMR (CDC13) 6 1,30-1,40 (m, 1H) , 1,46-1,64 (m, 1H) , 1,70-1,88 (m, 1H), 1,92-2,02 (m, 1H), 2,68-2,78 (m, 1H), 2,80-2,88 (m, 1H), 3,14-3,22 (m, 1H), 3,31 (d, 1H, J=12), 3,48 (d, 1H, J=12), 3,84 (d, 1H, J=3), 6,65 (d, 1H, J=6), 6,72 (d, 1H, J=3), 7,04-7,10 (m, 1H), 7,14-7,28 (m, 5H) .
HRMS Beregnet for C16H20N2S: 272,1342. Funnet: 272,1364. Beregnet for C16H20N2S-2HCl-0,6H20: C 53,96; H 6,57; N 7,87 Funnet: C 53,97; H 6,25; N 7,77
Eksempel 23
Cis- 3-( 2. 5- difluorbenzylamino)- 2- fenylpiperidin
Sm.p. 274-276°C (HCl-salt).
<1>H NMR (CDCI3) a 1,28-1,40 (m, 1H) , 1,44-1,62 (m, 1H) , 1,66-1,84 (m, 1H), 1,90-2,00 (m, 1H), 2,64-2,76 (m, 2H), 2,10-3,20 (rn, 1H) , 3,32 (d, 1H, J=12), 3,44 (d, 1H, J=12) , 3,81 (d, 1H, J=3), 6,50-6,58 (m, 1H), 6,62-6,78 (m, 2H), 7,10-7,26 (m, 5H). HRMS Beregnet for C18H20F2N2: 302,1590. Funnet: 302,1560. Beregnet for C18H20F2N2 • 2HC1 • 0 , 2H20: C 57,06; H 5,96; N 7,39 Funnet: C 56,94; H 5,94; N 7,37
Eksempel 24
( 2S, 3S)- 3- amino- 2- fenylpiperidin
I en kolbe ble plassert 31 g 10% palladium-karbon, 50 ml vann, 300 ml metanol, 450 ml etanol, 20 ml konsentrert, vandig saltsyre og 15 g (0,04 mol) av hydroklorid-saltet av (2S,3S)-3-(2-metoksybenzyl)amino-2-fenylpiperidin. Blandingen ble rystet under hydrogen (2,8 kg/cm<2>) i 1 dag og filtrert gjennom en pute av diatoméjord. Puten ble skyllet med 2N vandig saltsyre (HC1), vann, etanol og vann og konsentrert med en rotasjonsinndamper. Vann ble satt til residuet, og blandingen ble gjort basisk under anvendelse av 4N vandig natriumhydroksyd (NaOH). Blandingen ble ekstrahert med fire porsjo-ner diklormetan, og ekstraktene ble tørret over magnesium-sulfat (MgSOJ og konsentrert for å få 2,23 g av tittelforbindelsen. Den vandige fraksjonen ble konsentrert til tørrhet og utgnidd med kloroform. Konsentrasjon av kloroform-oppløsningen ga ytterligere 4,15 g av tittelforbindelsen. Produktet oppnådd på denne måten hadde spektral-egenskaper identiske med de til produktet ifølge Eksempel 1.
Eksempel 25
Cis- 3-( 2, 4- dimetoksybenzyl) amino- 2- fenylpiperidin <X>H NMR (CDCI3) 3 1,38 (m, 1H) , 1,65 (m, 1H) , 1,9 (m, 2H) , 2,15 (m, 1H), 2,8 (m, 2H), 3,25 (m, 1H), 3,35 (d, 1H, J=15), 3,4 (s, 3H), 3,6 (d, 1H, J=15), 3,78 (s, 3H), 3,85 (d, 1H, J=3), 6,25 (d, 1H, J=3), 6,35 (dd, 1H, J=10, 3), 6,85 (d, 1H, J=10), 7,30 (m, 5H).
Massespektrum m/z 32 6 (moder).
Analyse for C20H2SN2O2 • 2HC1:
Beregnet: C 60,14; H 7,07; N 7,02
Funnet: C 59,66; H 7,11; N 6,83
Eksempel 2 6
Cis- 3-( 2, 4- diklor- 6- metoksybenzyl) amino- 2- fenylpiperidin Sm.p. 256-258°C (HCl-salt).
'H NMR (CDC13) 6 1,4 (m, 1H) , 1,62 (m, 3H) , 1,94 (m, 1H) , 2,2 (m, 1H), 2,68 (m, 1H), 2,76 (m, 1H), 3,2 (m, 1H), 3,38 (s, 3H), 3,4 (d, 1H, J=10), 3,64 (d, 1H, J=10), 3,84 (m, 1H), 6,48 (d, 1H, J=3), 6,84 (d, 1H, J=3), 7,2 (m, 5H).
Masse-spektrum m/z 364 (moder).
Analyse for C19H22C12N20 • 2HC1:
Beregnet: C 52,07; H 5,52; N 6,39
Funnet: C 51,81; H 5,65; N 6,17
Eksempel 27
Cis- 3-( 2. 6- diklor- 4- metoksybenzyl) amino- 2- fenylpiperidin Sm.p. 230-240°C (HCl-salt).
<X>H NMR (CDCI3) 3 1,4 (m, 1H) , 1,6 (m, 3H) , 1,92 (m, 1H) , 2,16 (m, 1H), 2,76 (m, 2H), 3,2 (m, 1H), 3,58 (d, 1H, J=12), 3,70 (s, 3H), 3,74 (d, 1H, J=12), 3,86 (d, 1H, J=3), 6,66 (m, 2H), 7,2 (m, 5H).
Massespektrum m/z 364 (moder).
Analyse for C19H22C12N02 • 2HC1:
Beregnet: C 52,07; H 5,52; N 6,39
Funnet: C 52,18; H 5,46; N 6,24
Eksempel 2 8
Cis- 3-( 3, 4- diklor- 2- metoksybenzyl) amino- 2- fenylpiperidin Sm.p. 246-248° (HCl-salt).
<X>H NMR (CDCI3) 3 1,4 (m, 1H) , 1,65 (s, 2H) , 1,9 (m, 1H) , 2,05 (m, 2H), 2,8 (m, 2H), 3,25 (m, 1H), 3,45 (d, 1H, J=15), 3,6
(d, 1H, J=15), 3,9 (m, 4H), 6,65 (d, 1H, J=10), 6,90 (d, 1H, J=10), 7,3 (m, 5H) .
HRMS Beregnet for C19H22C12N20 • 2HC1: C 52,07; H 5,52; N 6,39 Funnet: C 51,58; H 5,46; N 6,26
Eksempel 29
Cis- 3-( 2. 3- dimetoksybenzyl) amino- 2- fenylpiperidin
Sm.p. 238-240°C (HCl-salt).
<X>H NMR (CDC13) 5 1,44 (m, 1H) , 1,6 (m, 1H) , 2,00 (m, 2H) , 2,8 (dt, 2H, J=12, 3), 2,92 (m, 1H), 3,26 (m, 1H), 3,42 (d, 1H, J=10), 3,52 (s, 3H), 3,53 (d, 1H, J=10), 3,78 (s, 3H), 3,84 (m, 1H), 3,90 (d, 1H, J=3), 6,52 (d, 1H, J=10), 6,72 (d, 1H, J=10), 6,84 (d, 1H, J=10), 7,82 (m, 5H).
HRMS Beregnet for C20H26N2O2: 326,2058. Funnet: 326,1991. Analyse for C20H26N202 • 2HC1 • 1/2 H20:
Beregnet: C 58,82; H 7,16; N 6,86
Funnet: C 58,63; H 7,26; N 6,81
Eksempel 30
Cis- 3-( 5- brom- 2- metoksy- 3- metylbenzyl) amino- 2- fenylpiperidin Sm.p. 236-238°C (HCl-salt).
'H NMR (CDC13) 6 1,44 (m, 1H) , 1,64 (m, 1H) , 1,90 (m, 1H) , 2,16 (s, 3H), 2,80 (m, 2H), 3,26 (m, 1H), 3,36 (d, 1H, J=12), 3,43 (s, 1H), 3,52 (d, 1H, J=12), 3,90 (m, 1H), 6,92 (s, 1H), 7,10 (s, 1H) , 7,34 (m, 5H) .
HRMS Beregnet for C20H2SBrN20: 388,1144. Funnet: 388,1153.
Eksempel 31
( 2S. 3S)- 3-( 2. 4- dimetoksybenzyl) amino- 2- fenylpiperidin <X>H NMR (CDCI3) 3 1,4 (m, 1H) , 1,58 (m, 1H) , 1,94 (m, 2H) , 2,1 (m, 1H), 2,8 (m, 2H), 3,28 (m, 1H), 3,34 (d, 1H, J=15), 3,38 (s, 3H), 3,64 (d, 1H, J=15), 3,76 (s, 3H), 3,88 (d, 1H, J=3), 6,24 (d, 1H, J=3), 6,30 (dd, 1H, J=10, 3), 6,86 (d, 1H, J=10), 7,26 (m, 5H).
HRMS Beregnet for C20H26N202: 326,1988. Funnet: 326,1986. Analyse for C20H26N2O2 • 2HC1 • 1/4H20 :
Beregnet: C 59,48; H 7,11; N 6,94
Funnet: C 59,40; H 6,96; N 6,95.
Eksempel 32
( 2S. 3S)- 3-( 2- cyklopentyloksybenzyl) amino- 2- fenylpiperidin Sm.p. 230-232°C (HCl-salt).
<X>H NMR (CDC13) 5 1,75 (m, 13H) , 2,14 (m, 1H) , 2,80 (dt, 2H, J=12, 3), 2,90 (m, 1H), 3,28 (m, 1H), 3,36 (d, 1H, J=15), 3,60 (d, 1H, J=15), 3,88 (bred s, 1H), 4,58 (m, 1H), 6,74 (m, 2H), 6,84 (d, 1H, J=10), 7,12 (m, 1H), 7,30 (m, 5H).
HRMS Beregnet for C23H40N2O: 350,2351. Funnet: 350,2332. Analyse for C23H30N2O • 2HC1 • 2H20 :
Beregnet: C 60,12; H 7,33; N 6,10
Funnet: C 59,10; H 7,19; N 6,09.
Eksempel 33
( 2S. 3S)- 3-( 2- cyklopentyloksy- 5- metoksybenzyl) amino- 2- fenylpiperidin
Sm.p. 217-219°C (HCl-salt).
'H NMR (CDC13) 6 1,66 (m, 13H) , 2,14 (m, 1H) , 2,82 (dt, 2H, J=12, 3), 2,92 (m, 1H), 3,14 (m, 2H), 3,54 (d, 1H, J=15), 3,72 (s, 3H), 3,90 (d, 1H, J=15), 4,50 (m, 1H), 6,64 (m, 3H), 7,30 (m, 5H) .
HRMS Beregnet for C24H32N202: 380,2456. Funnet: 380,2457. Analyse for C24H32N202 - 2HC1-H20:
Beregnet: C 60,14; H 7,70; N 5,94
Funnet: C 61,05; H 7,67; N 5,92.
Eksempel 34
( 2S. 3S)- 3-( 5- tert- butyl- 2- metoksybenzyl) amino- 2- fenylpiperidin Sm.p. 262-264°C (HCl-salt).
<1>H NMR (CDCI3) 5 1,22 (s, 9H) , 1,38 (m, 2H) , 1,90 (m, 1H) , 2,14 (m, 1H), 2,80 (m, 2H), 3,26 (m, 1H), 3,36 (d, 1H, J=15), 3,44 (S., 3H) , 3,62 (d, 1H, J=15) , 3,86 (d, 1H, J=3), 6,60 (d, 1H, J=10), 7,00 (d, 1H, J=3), 7,12 (m, 1H), 7,26 (m, 5H).
HRMS Beregnet for C23H32N20: 352,2507. Funnet: 352,2512. Analyse for C23H32N20 • 2HC1 • 0, 5H20:
Beregnet: C 63,58; H 8,12; N 6,45
Funnet: C 63,75; H 8,00; N 6,42.
Eksempel 35
( 2S. 3S)- 3-( 5- sek- butyl- 2- metoksybenzyl) amino- 2- fenylpiperidin Sm.p. 260-263°C (HCl-salt).
<X>H NMR (CDC13) 6 0,8 (2t, 3H, J=6) , 1,16 (2d, 3H, J=7) , 1,5 (m, 4H), 1,9 (m, 1H), 2,12 (m, 1H), 2,46 (m, 1H), 2,8 (m, 3H), 3,28 (m, 1H), 3,42 (d, 1H, J=15), 3,44 (s, 3H), 3,66 (d, 1H, J=15), 3,90 (d, 1H, J=3), 6,60 (d, 1H, J=10), 6,78 (bred s, 1H), 6,92 (d, 1H, J=10), 7,3 (m, 5H).
HRMS Beregnet for C23H32N20: 352,2507. Funnet: 352,2525. Analyse for C23H32N20-2HC1-H20:
Beregnet: C 62,29; H 8,18; N 6,32
Funnet: C 62,95; H 7,62; N 6,61.
Eksempel 3 6
( 2S. 3S)- 3-( 5- fluor- 2- metoksybenzylamino)- 2- fenylpiperidin Sm.p. > 270°C (HCl-salt).
<*>H NMR (CDCI3) 6 1,38 (m, 1H) , 1,56 (m, 1H) , 1,90 (m, 1H) , 2,06 (m, 1H), 2,66 (m, 2H), 3,26 (m, 1H), 3,30 (d, 1H, J=15), 3,38 (s, 3H), 3,56 (d, 1H, J=15), 3,86 (d, 1H, J=3), 6,52 (m, 1H), 6,64 (dd, 1H, J=10, 3), 6,70 (dt, 1H, J=10, 3), 7,24 (m, 5H). Analyse for C19H23FN20 • 5HC1 • 0, 75H20:
Beregnet: C 57,57; H 6,61; N 7,06
Funnet: C 57,83; H 6,31; N 7,06.
Eksempel 3 7
( 2S, 3S)- 3-( 4, 5- difluor- 2- metoksybenzyl) amino- 2- fenylpiperidin XH NMR (CDC13) 6 1,36 (m, 1H) , 1,55 (m, 1H) , 1,84 (m, 1H) , 2,02 (m, 1H), 2,72 (m, 2H), 3,20 (m, 1H), 3,26 (d, 1H, J=14), 3,42 (S, 3H), 3,52 (d, 1H, J=14), 3,84 (d, 1H, J=3), 6,42 (dd, 1H, J=6, 12), 6,70 (dd, 1H, J=8, 10), 7,20 (m, 5H).
Analyse for C19H22F2N20 • 2HC1 • 0, 55H20:
Beregnet: C 54,96; H 6,09; N 6,75
Funnet: C 54,65; H 5,69; N 6,74.
Eksempel 3 8
( 2S. 3S)- 3-( 2- acetamidobenzyl) amino- 2- fenylpiperidin
Sm.p. 187-195°C (HCl-salt).
<*>H NMR (CDCI3) 8 1,52 (m, 1H) , 1,61 (s, 3H) , 1,70 (m, 1H) , 2,10 (m, 2H) , 2,80 (m, 2H), 3,18 (m, 1H), 3,32 (d, 1H, J=16), 3,54 (d, 1H, J=16), 3,89 (d, 1H, J=3), 6,88 (m, 2H), 7,26 (m, 7H). HRMS Beregnet for C20H2SN30: 323,1997. Funnet: 323,1972.
Eksempel 39
( 2S, 3S)- 3-( 2- metoksybenzyl) amino- 2- fenylpiperidin
NMR (CDCI3) 6 1,36 (m, 1H) , 1,54 (m, 1H) , 2,0 (m, 2H) , 2,78 (m, 2H) , 3,23 (m, 1H), 3,36 (d, 1H, J=14), 3,41 (s, 3H) , 3,63 (d, 1H, J=14), 3,83 (bred s, 1H), 6,61 (d, 1H, J=8), 6,74 (t, 1H, J=7), 6,91 (d, 1H, J=7), 7,08 (t, 1H, J=8), 7,12 (m, 5H).
Eksempel 40
( 2S. 3S) - 3-( 2- metoksy- 5- metylmerkaptobenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. 257-259°C (dek.).
'H NMR (fri base; CDC13) 6 1,32 (m, 1H) , 1,50 (m, 1H) , 1,82 (m, 1H), 2,04 (m, 1H), 2,30 (s, 3H), 2,72 (m, 2H), 3,18 (m, 1H), 3,26 (d, 1H, J=15), 3,36 (s, 3H), 3,54 (d, 1H, J=15), 3,80 (d,
1H, J=3), 6,52 (d, 1H, J=10) , 6,90 (d, 1H, J=3), 7,04 (dd, 1H, J=3, 10), 7,2 (m, 5H).
HRMS Beregnet for C20H26N2OS: 342,1760. Funnet: 342,1770. Analyse for C20H26N2OS • 2HC1 • 0, 25H20:
Beregnet: C 57,20; H 6,84; N 6,67.
Funnet: C 57,35; H 6,76; N 6,61.
Eksempel 41
( 2S. 3S)- 3- ( 2- metoksy- 5- metvlsulfoksybenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. 209°C (dek.).
<*>H NMR (fri base; CDC13) 5 1,40 (m, 1H) , 1,56 (m, 1H) , 1,90 (m, 1H), 2,10 (m, 1H), 2,59, 2,62 (2S, 3H), 2,76 (m, 2H), 3,22 (m, 1H), 3,42 (m, 1H), 3,49, 3,52 (2S, 3H), 3,66 (m, 1H), 3,86 (d, 1H, J=3), 6,76 (m, 1H), 7,24 (m, 6H), 7,46 (m, 1H).
HRMS Beregnet for C20H27N2O2S (M+l) : 359,1787. Funnet: 359,1763.
Eksempel 42
( 2S. 3S)- 3-( 2- metoksy- 5- metylsulfonylbenzylamino)- 2- fenyl-pi<p>eridin- h<y>droklorid
Sm.p. > 260°C.
<*>H NMR (fri base; CDC13) 6 1,40 (m, 1H) , 1,58 (m, 1H) , 1,88 (m, 1H), 2,10 (m, 1H), 2,78 (m, 2H), 2,96 (s, 3H), 3,24 (m, 1H), 3,38 (d, 1H, J=15), 3,54 (s, 3H), 3,66 (d, 1H, J=15), 3,90 (d, 1H, J=3), 6,74 (d, 1H, J=10), 7,26 (m, 5H), 7,58 (d, 1H, J=3), 7,72 (d, 1H, J=10).
HRMS Beregnet for C20H26N2O3S: 374,1658. Funnet: 374,1622.
Eksempel 43
( 2S. 3S)- 3-( 2- metoksy- 5- fenoksybenzylamino)- 2- fenylpiperidin-hydroklorid
Sm.p. > 250°C.
<X>H NMR (fri base; CDC13) 6 1,34 (m, 1H) , 1,74 (m, 2H) , 2,06 (m, 1H), 2,76 (m, 2H), 3,22 (m, 1H), 3,32 (d, 1H, J=15), 3,44 (s, 3H), 3,60 (d, 1H, J=15), 3,85 (d, 1H, J=3), 6,60 (d, 1H, J=9), 6,67 (d, 1H, J=3), 6,78 (dd, 1H, J=6,9), 6,86 (d, 2H), 7,00 (t, 1H, J=6), 7,22 (ra, 7H).
HRMS Beregnet for C25H28N202: 388,2151. Funnet: 382,2137.
Eksempel 44
( 2S. 3S)- 3-( 2- metoksy- 5- N- metylmetylsulfonamido- benzylamino)- 2-fenylpiperidin- hydroklorid
<X>H NMR (fri base; CDC13) 6 1,42 (m, 1H) , 1,74 (m, 2H) , 2,12 (m, 1H), 2,78 (m, 5H), 3,20 (s, 3H), 3,24 (m, 1H), 3,36 (d, 1H, J=15) , 3,52 (s, 3H) , 3,64 (d, 1H, J=15), 3,89 (d, 1H, J=3), 6,64 (d, 1H, J=9), 6,98 (d, 1H, J=3) , 7,14 (dd, 1H, J=3, 9), 7,26 (m, 5H).
HRMS Beregnet for C21H29N303S: 403,1992. Funnet: 403,1923. Analyse for C21H29N303S • 2HC1 • l/3H20:
Beregnet: C 52,28; H 6,61; N 8,71.
Funnet: C 52,09; H 6,63; N 8,68.
Eksempel 45
( 2S. 3S)- 3-( 2. 2. 2- trifluoretoksybenzylamino)- 2- fenylpiperidin-hydroklorid
Sm.p. > 275°C.
<X>H NMR (fri base; CDC13) 6 1,44 (m, 1H) , 1,62 (m, 1H) , 1,9.0 (m, 1H), 2,10 (m, 1H), 2,82 (m, 2H) , 3,26 (m, 1H) , 3,38 (d, 1H, J=15), 3,66 (d, 1H, J=15), 3,92 (d, 1H, J=3), 4,06 (m, 2H), 6,66 (d, 1H, J=10), 6,94 (m, 2H), 7,16 (m, 1H), 7,30 (m, 5H) . HRMS Beregnet for C20H24F3N20 (M+l) : 365,1835. Funnet: 385,1908. Analyse for C20H23F3N2O-2HCl-l/3H2O:
Beregnet: C 54,19; H 5,84; N 6,32
Funnet: C 54,22; H 5,57; N 6,42.
Eksempel 46
( 2S, 3S)- 3- r5- klor- 2-( 2, 2, 2- trifluoretoksy) benzylaminol- 2-fenylpiperidin- hydroklorid
Sm.p. 267-269°C.
<X>H NMR (fri base; CDC13) 6 1,40 (m, 1H) , 1,60 (m, 1H) , 1,82 (m, 1H), 2,02 (m, 1H), 2,76 (m, 2H), 3,20 (m, 1H), 3,28 (d, 1H, J=15), 3,52 (d, 1H, J=15), 3,84 (d, 1H, J=3), 4,00 (m, 2H), 6,54 (d, 1H, J=10) , 6,92 (d, 1H, J=3), 7,04 (m, 1H) , 7,24 (m, 5H) .
HRMS Beregnet for C20H22ClF3N20: 398,1368. Funnet: 398,1352. Analyse for C20H22C1F3N20 • 2HC1:
Beregnet: C 50,91; H 5,13; N 5,94.
Funnet: C 50,89; H 4,84; N 5,93.
Eksempel 47
( 2S. 3S)- 3-( 3- trifluormetoksybenzylamino)- 2- fenylpiperidin-hydroklorid
Sm.p. > 275°C
<X>H NMR (fri base; CDC13) 6 1,4 (m, 1H) , 1,54 (m, 1H) , 1,80 (m, 1H), 1,96 (m, 1H), 2,74 (m, 2H), 3,18 (m, 1H), 3,30 (d, 1H, J=15), 3,46 (d, 1H, J=15), 3,82 (d, 1H, J=3), 6,80 (s, 1H), 6,84 (d, 1H, J=10), 6,92 (m, 1H), 7,12 (m, 1H), 7,24 (m, 5H). HRMS Beregnet for C19H21F3N20: 350,1601. Funnet: 350,1609. Analyse for C19H21F3N20 • 2HC1:
Beregnet: C 53,91; H 5,48; N 6,62
Funnet: C 53,84; H 5,07; N 6,59.
Eksempel 48
( 2S. 3S)- 3-( 5- t- butyl- 2- trifluormetoksybenzylamino) - 2- fenylpiperidin- hydroklorid
Sm.p. 262-264°C
'H NMR (fri base; CDC13) 5 1,20 (s, 9H) , 1,40 (m, 1H) , 1,52 (m, 1H), 1,84 (m, 1H), 2,06 (m, 1H), 2,80 (m, 2H), 3,22 (m, 1H),
3,38 (d, 1H, J=15), 3,58 (d, 1H, J=15), 3,86 (d, 1H, J=3), 6,98 (m, 1H), 7,12 (m, 2H), 7,26 (m, 5H).
HRMS Beregnet for C23H29F3N20: 406,2225. Funnet: 406,2271. Analyse for C23H29F3N20 • 2HC1 • 1/3H20:
Beregnet: C 56,92; H 6,56; N 5,77
Funnet: C 56,99; H 6,41; N 6,03.
Eksempel 49
( 2S. 3S)- 3- r5- isopropyl- 2-( 2, 2, 2- trifluoretoksy)- benzylaminol - 2- fenylpiperidin- hydroklorid
Sm.p. > 280°C
<X>H NMR (fri base; CDC13) 6 1,12 (m, 6H) , 1,4 (m, 1H) , 1,62 (m, 1H), 1,82 (m, 1H), 2,08 (m, 1H), 2,76 (m, 3H), 3,22 (m, -1H), 3,30 (d, 1H, J=15), 3,38 (d, 1H, J=15), 3,82 (d, 1H, J=3), 4,02 (m, 2H), 6,56 (d, 1H, J=10), 6,78 (d, 1H, J=3), 6,94 (m, 1H), 7,24 (m, 5H).
HRMS Beregnet for C23H30F3N2O (M+l) : 407,2303. Funnet: 407,2287. Analyse for C23H29F3N20 • 2HC1 • 1/2H20:
Beregnet: C 56,55; H 6,60; N 5,70
Funnet: C 56,17; H 6,39; N 5,77.
Eksempel 50
( 2S. 3S)- 3-( 2- metoksy- 5- metylaminometylbenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. 242°C (dek.).
<X>H NMR (fri base; CDC13) 6 1,36 (m, 1H) , 1,58 (m, 1H) , 1,90 (m, 1H), 2,10 (m, 1H), 2,38 (s, 3H), 2,80 (m, 2H), 3,22 (m, 1H), 3,42 (m, 4H), 3,56 (s, 2H), 3,64 (d, 1H, J=15), 3,86 (d, 1H, J=3), 6,60 (d, 1H, J=10), 6,86 (d, 1H, J=3), 7,02 (m, 1H) , 7,26 (m, 5H).
HRMS Beregnet for C21H30N30 (M+l): 340,2382. Funnet: 340,2400.
Eksempel 51
( 2S, 3S)- 3- r5- dimetylamino- 2-( 2, 2, 2- trifluoretoksy)- benzylaminol- 2 - fenylpiperidin- hydroklorid
Sm.p. 250-252°C.
<X>H NMR (fri base; CDC13) 6 1,40 (m, 1H) , 1,60 (m, 1H) , 1,86 (m, 1H), 2,10 (m, 1H), 2,82 (m, 8H), 3,22 (m, 1H), 3,34 (d, 1H, J=15), 3,58 (d, 1H, J=15), 3,88 (d, 1H, J=3), 4,00 (m, 2H), 6,42 (d, 1H, J=3), 6,50 (m, 1H), 6,64 (d, 1H, J=10), 7,30 (m, 5H) .
HRMS Beregnet for C22H28F3N30: 407,2178. Funnet: 407,2179.
Eksempel 52
( 2S. 3S)- 3-( 2- difluormetoksy- 5- metylmerkaptobenzylamino)- 2-fenylpiperidin- hydroklorid
Sm.p. 254-256°C.
<X>H NMR (fri base; CDC13) 6 1,45 (m, 1H) , 1,60 (m, 1H) , 1,80 (m, 1H), 2,10 (m, 1H), 2,40 (s, 3H), 2,80 (m, 2H), 3,20 (m, 1H), 3,30 (d, 1H, J=15), 3,55 (d, 1H, J=15), 3,90 (d, 1H, J=3), 6,10 (t, 1H, J=85), 6,95 (m, 3H), 7,25 (m, 5H).
HRMS Beregnet for C20H25C12F2N2OS (M+l) : 379,1650. Funnet: 379,1668.
Analyse for C20H24N2OF2C12 • 2HC1 • 1/4H20:
Beregnet: C 52,69; H 5,86; N 6,14
Funnet: C 52,36; H 5,86; N 6, 14.
Eksempel 53
( 2S. 3S)- 3-( 5- sek- butyl- 2- metoksybenzyl) amino- 2- fenylpiperidin Sm.p. 260-263°C (HCl-salt).
<1>H NMR (fri base; CDC13) 6 0,8 (2t, 3H, J=6) , 1,16 (2d, 3H, J=7) , 1,5 (m, 4H) , 1,9 (m, 1H), 2,12 (m, 1H), 2,46 (m, 1H), 2,8 (m, 3H), 3,28 (m, 1H), 3,42 (d, 1H, J=15), 3,44 (s, 3H), 3,66 (d, 1H, J=15), 3,90 (d, 1H, J=3), 6,60 (d, 1H, J=10), 6,78 (bred s, 1H), 6,92 (d, 1H, J=10), 7,3 (m, 5H).
HRMS Beregnet for C23H32N20: 352,2507. Funnet: 352,2525.
Eksempel 54
( 2S, 3S)- 3-( 4- amino- 5- klor- 2- metoksybenzyl) amino- 2- fenylpiperidin- hydroklorid
Sm.p. 200-203°C (dek.).
<X>H NMR (fri base; CDC13) 5 1,35 (m, 1H) , 1,56 (m, 1H) , 1,86 (m, 1H), 2,05 (m, 1H), 2,75 (m, 2H), 3,22 (m, 2H), 3,36 (s, 3H), 3,48 (d, 1H, J=12), 3,84 (d, 1H, J=2), 6,08 (s, 1H), 6,78 (s, 1H), 7,24 (m, 5H).
HRMS Beregnet for C19H24C1N30: 345,1604. Funnet: 345,1589.
Eksempel 55
( 2S. 3S)- 3-( 2- metoksy- 5- fenylbenzylamino)- 2- fenylpiperidin-hydroklorid
Sm.p. 238-239°C (dek.).
<X>H NMR (fri base; CDC13) 6 1,38 (m, 1H) , 1,60 (m, 1H) , 1,88 (m, 1H), 2,12 (m, 1H), 2,80 (m, 2H), 3,23 (m, 1H), 3,45 (m, 4H), 3,70 (d, 1H, J=12), 3,86 (d, 1H, J=3) , 6,70 (d, 1H, J=6) , 7,34 (m, 12H).
HRMS Beregnet for C25H28N20: 372,2197. Funnet: 372,2172.
Eksempel 56
( 2S. 3S)- 2- fenyl- 3-( kinolin- 8- yl) metylpiperidin- hydroklorid Sm.p. 252-253°C (dek.).
<X>H NMR (fri base; CDC13) 6 1,38 (m, 1H) , 1,58 (m, 1H) , 1,94 (m, 1H), 2,17 (m, 1H), 2,78 (m, 2H), 3,24 (m, 1H), 3,83 (d, 1H, J=3), 3,96 (d, 1H, J=15), 4,28 (d, 1H, J=15), 7,14 (m, 6H), 7,32 (m, 2H), 7,58 (t, 1H, J=4), 7,98 (d, 1H, J=6), 8,46 (m, 1H) .
HRMS Beregnet for C21H23N3: 317,1887. Funnet: 317,1883.
Eksempel 57
( 2S. 3S)- 3-( 5- heptyloksy- 2- metoksybenzyl) amino- 2- fenylpiperidin- hydroklorid
Sm.p. 230°C (dek.).
<X>H NMR (fri base; CDC13) 6 0,90 (m, 2H) , 1,38 (m, 10H) , 1,76 (m,. 4H) , 2,12 (m, 1H) , 2,80 (m, 2H) , 3,26 (m, 1H) , 3,38 (d, 1H, J=16), 3,42 (s, 3H), 3,62 (d, 1H, J=15), 3,82 (t, 2H, J=6), 3,88 (d, 1H, J=3), 6,62 (m, 3H), 7,28 (m, 5H).
HRMS Beregnet for C26H38N202: 410,2928. Funnet: 410,2953.
Eksempel 58
( 2S. 3S)- 3-( 2- heptyloksy- 5- metoksybenzyl) amino- 2- fenylpiperidin- hydroklorid
Sm.p. 212-213°C (dek.)
<*>H NMR (fri base; CDC13) 6 0, 90 (m, 3H) , 1,60 (m, 13H) , 2,12 (m, 1H), 2,80 (m, 2H), 3,26 (m, 1H), 3,36 (d, 1H, J=15), 3,62 (m, 6H), 3,86 (d, 1H, J=3), 6,60 (m, 3H), 7,23 (m, 5H).
HRMS Beregnet for C26H38N202: 410,2928. Funnet: 410,2912.
Eksempel 59
( 2S. 3S)- 3-( 5- heptyl- 2- metoksybenzyl) amino- 2- fenylpiperidin-hydroklorid
Sm.p. 242-243°C (dek.).
<X>H NMR (fri base; CDC13) 6 0, 88 (m, 3H) , 1,60 (m, 13H) , 2,14 (m, 1H), 2,44 (t, 2H, J=6), 2,78 (m, 2H), 3,26 (m, 1H), 3,40 (m, 4H), 3,64 (d, 1H, J=15), 3,86 (d, 1H, J=2), 6,58 (d, 1H, J=6), 6,75 (d, 1H, J=2), 6,92 (d, 1H, J=6), 7,26 (m, 5H). HRMS Beregnet for C2SH38N20: 394,2977. Funnet: 394,3009.
Eksempel 60
( 2S, 3S)- 3-( 2- metoksy- 5- n- propylbenzyl) amino- 2- fenylpiperidin-hydroklorid
Sm.p. 245-247°C (dek.).
<X>H NMR (fri base; CDC13) a 0,9 (t, 3H, J=10), 1,4 (m, 1H), 1,54 (m, 2H), 1,92 (m, 1H), 2,14 (m, 1H), 2,44 (t, 2H, J=6), 2,80 (m, 2H), 3,26 (s, 1H), 3,40 (d, 1H, J=15), 3,44 (s, 3H), 3,66 (d, 1H, J=15), 3,90 (s, 1H), 6,56 (d, 1H, J=10), 6,76 (s, 1H), 6,92 (d, 1H, J=10), 7,26 (m, 5H).
HRMS Beregnet for C22H30N2O: 338,2351. Funnet: 338,2339. Analyse for C22H30N20 • 2HC1 • 0, 25H20:
Beregnet: C 63,57; H 7,81; N 6, 74
Funnet: C 63,59; H.7,66; N 6,73.
Eksempel 61
( 2S. 3S)- 3-( 4, 5- dimetyl- 2- metoksybenzyl) amino- 2- fenylpiperidin-hydroklorid
Sm.p. 269-270°C.
<X>H NMR (fri base; CDC13) 5 1,40 (m, 1H) , 1,60 (ra, 1H) , 1,96 (m, 2H), 2,14 (s, 3H) , 2,18 (s, 3H) , 2,80 (m, 2H), 3,30 (m, 1H), 3,40 (d, 1H, J=15), 3,42 (s, 3H), 3,62 (d, 1H, J=15), 3,90 (d, 1H, J=3), 6,48 (s, 1H), 6,70 (s, 1H), 7,28 (m, 5H).
HRMS Beregnet for C21H28N20: 324,2195. Funnet: 324,2210. Analyse for C21H2BN20 • 2HC1 • 0, 25H20:
Beregnet: C 62,80; H 7,60; N 6,99
Funnet: C 62,64; H 7,31; N 6,86
Eksempel 62
( 2S. 3S)- 3-( 5- t- butyl- 2- hydroksybenzyl) araino- 2- fenylpiperidin-hydroklorid
Sm.p. 267-269°C (dek.).
<X>H NMR (fri base; CDC13) 6 1,3 (s, 9H) , 1,6 (m, 3H) , 2,18 (m, 1H), 2,82 (m, 1H), 2,98 (m, 1H) , 3,22 (m, 1H), 3,44 (d, 1H, J=15) , 3,56 (d, 1H, J=15) , 3,92 (ra, 1H) , 6,70 (rtl, 2H) , 7,14 (m, 1H), 7,40 (m, 5H).
HRMS Beregnet for C22H30N20: 338,2351. Funnet: 338,2384.
Eksempel 63
( 2S. 3S) - 3-( 5- karbometoksy- 2- metoksybenzyl) amino- 2- fenylpiperidin- hydroklorid
Sm.p. 238-240°C.
<*>H NMR (fri base; CDC13) <5 1,4 (m, 1H) , 1,6 (m, 1H) , 1,88 (m, 1H), 2,1 (m, 1H), 2,75 (m, 2H), 3,2 (m, 1H), 3,35 (d, 1H, J=15) , 3,45 (s, 3H) , 3,7 (d, 1H, J=15), 3,85 (m, 4H) , 6,65 (d, 1H, J=10), 7,2 (m, 5H), 7,70 (d, 1H, J=3) , 7,85 (m, 1H) .
HRMS Beregnet for C21H26N203: 354,193 7. Funnet: 354,1932.
Eksempel 64
( 2S. 3S)- 3-( 5- n- butyl- 2- metoksybenzyl) amino- 2- fenylpiperidin-hydroklorid
Sm.p. 252-253°C.
<X>H NMR (fri base; CDC13) 3 0, 88 (t, 3H, J=10) , 1,38 (m, 3H) , 1,56 (m, 3H), 1,96 (m, 2H), 2,18 (m, 1H), 2,50 (t, 2H, J=10), 2,86 (m, 2H) , 3,30 (m, 1H), 3,44 (d, 1H, J=15), 3,48 (s, 3H), 3,68 (d, 1H, J=15), 3,82 (d, 1H, J=3), 6,62 (d, 1H, J=10), 6,80 (s, 1H) , 6,86 (d, 1H, J=10), 7,3 (m, 5H).
HRMS Beregnet for C23H32N20: 352,2507. Funnet: 352,2509. Analyse for C23H32N20 • 2HC1 • 1/3H20:
Beregnet: C 64,03; H 8,09; N 6,50
Funnet: C 64,39; H 7,90; N 6,59.
Eksempel 65
( 2S. 3S)- 3-( 5- isopropyl- 2- metoksybenzyl) amino- 2- fenylpiperidin-hydroklorid
Sm.p. 252-254°C.
<*>H NMR (fri base; CDC13) 6 1,14 (d, 6H, J=6) , 1,36 (m, 1H) , 1,58 (m, 1H), 1,88 (m, 1H), 2,1 (m, 1H), 2,76 (m, 3H), 3,24 (m, 1H), 3,36 (d, 1H, J=15), 3,42 (s, 3H), 3,60 (d, 1H, J=15), 3,86 (d, 1H, J=3), 6,56 (d, 1H, J=10), 6,80 (d, 1H, J=3), 6,84 (m, 1H) , 7,24 (m, 5H) .
HRMS Beregnet for C22H30N2O: 338,2351. Funnet: 338,2377.
Analyse for C22H30N2O • 2HC1 • 1/4H20 :
Beregnet: C 63,52; H 7,88; N 6,74
Funnet: C 63,33; H 7,64; N 6,75.
Eksempel 66
( 2S, 3S) - 3-( 2- difluormetoksy- 5- N, N- dimetylaminobenzylamino)- 2-fenylpiperidin- hydroklorid
Sm.p. 243-245°C (dek.).
<1>H NMR (fri base; CDC13) 6 1,44 (m, 1H) , 1,72 (m, 2H) , 2,10 (m, 1H), 2,84 (m, 8H), 3,21 (m, 1H), 3,28 (d, 1H, J=15), 3,55 (d, 1H, J=15), 3,88 (d, 1H, J=3), 6,08 (t, 1H, J=72), 6,36 (d, 1H, J=3) , 6,46 (dd, 1H, J=3,9), 6,86 (d, 1H, J=9) , 7,28 (m, 5H) . HRMS Beregnet for C21H27F2N30: 375,2122. Funnet: 375,2138. Analyse for C21H27F2N30 • 3HC1 • 1/2H20:
Beregnet: C 51,07; H 6,44; N 8,51.
Funnet: C 50,71; H 6,08; N 8,28.
Eksempel 67
( 2S. 3S)- 3-\ 2 , 5 Tbis-( difluormetoksy) benzyl) aminol- 2- fenylpiperidin- hydroklorid
Sm.p. 238-239°C.
<X>H NMR (fri base,- CDC13) 6 1,64 (m, 3H) , 2,04 (m, 1H) , 2,76 (m, 2H) , 3,18 (m, 1H), 3,28 (d, 1H, J=12), 3,52 (d, 1H, J=12), 3,84 (d, 1H, J=3), 6,12 (t, 1H, J=75), 6,40 (t, 1H, J=75), 6,75 (m, 2H), 6,94 (d, 1H, J=9), 7,24 (m, 5H).
HRMS Beregnet for C20H22F4N2O2: 398,1612. Funnet: 398,1591.
Eksempel 68
( 2S. 3S)- 3-( 5- t- butyl- 2- difluormetoksybenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. 263-264°C (dek.).
'H NMR (fri base; CDC13) 6 1,24 (s, 9H) , 1,42 (m, 1H) , 1,62 (m, 1H), 1,80 (m, 1H), 2,10 (m, 1H), 2,80 (m, 2H), 3,24 (m,
2H) , 3,58 (d, 1H, J=12), 3,87 (brs, 1H), 6,18 (t, 1H, J=72), 6,86 (d, 1H, J=6) 7,00 (brs, 1H), 7,12 (m, 1H), 7,24 (m, 5H). HRMS Beregnet for C23H30F2N2O: 388,2321. Funnet: 3 88,2336.
Eksempel 69
( 2S. 3S)- 3-( 5- dimetylamino- 2- metoksybenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. > 275°C,
<X>H NMR (fri base,- CDC13) 3 1,34 (m, 1H) , 1,70 (m, 2H) , 2,10 (m, 1H), 2,76 (m, 8H), 3,20 (m, 1H), 3,34 (m, 4H), 3,56 (d, 1H, J=12), 3,82 (d, 1H, J=2), 6,50 (m, 3H), 7,22 (m, 5H).
HRMS Beregnet for C21H29N30: 339,2306. Funnet: 339,2274. Analyse for C21H29N30 • 3HC1-H20:
Beregnet: C 54,02; H 7,34; N 9,00
Funnet: . C 53,84; H 7,55; N 8,92.
Eksempel 70
( 2S. 3S)- 3- ( 2- isopropoksy- 5- trifluormetoksybenzylamino)- 2-fenylpiperidin- hydroklorid
Sm.p. 245-246°C (dek.).
<X>H NMR (fri base; CDC13) 3 1,08 (d, 3H, J=6) , 1,12 (d, 3H, J=6), 1,40 (m, 1H), 1,64 (m, 1H), 1,87 (m, 1H), 2,08 (m, 1H), 2,78 (m, 2H), 3,02 (m, 1H), 3,34 (d, 1H, J=15), 3,51 (d, 1H, J=15), 3,85 (d, 1H, J=2), 4,28 (m, 1H), 6,01 (d, 1H, J=9), 6,82 (m, 1H), 6,91 (m, 1H), 7,24 (m, 5H).
HRMS Beregnet for C22H27F3N202: 408,2024. Funnet: 408,2019. Analyse for C22H27F3N202 • 2HC1:
Beregnet: C 54,89; H 6,07; N 5,82
Funnet: C 54,50; H 6,24; N 5,78.
Eksempel 71
( 2S. 3S)- 3-( 2- difluormetoksy- 5- trifluormetoksy- benzylamino)- 2-fenylpiperidin- hydroklorid
Sm.p. 257-259°C (dek.)
<X>H NMR (fri base; CDC13) 6 1,44 (m, 1H) , 1,58 (m, 1H) , 1,78 (m, 1H) , 2,03 (m, 1H), 2,78 (m, 2H) , 3,20 (m, 1H) , 3,32 (d, 1H, J=15), 3,54 (d, 1H, J=15), 3,87 (d, 1H, J=2), 6,15 (t, 1H, J=72), 6,94 (m, 3H), 7,26 (m, 5H).
HRMS Beregnet for C20H21FSN202: 416,1523. Funnet: 416,1501. Analyse for C20H21F5N2O2 • 2HC1 • l/3H20:
Beregnet: C 48,50; H 4,81; N 5,65.
Funnet: C 48,45; H 4,57; N 5,66.
Eksempel 72
( 2S, 3S)- 3-( 2- etoksy- 5- trifluormetoksybenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. > 275°C (dek.).
<X>U NMR (fri base; CDC13) <5 1,13 (t, 3H, J=6) , 1,38 (m, 1H) , 1,70 (m, 2H), 2,06 (m, 1H), 2,74 (m, 2H), 3,22 (m, 1H), 3,30 (d, 1H, J=15), 3,68 (m, 3H), 3,84 (br s, 1H), 6,55 (d, 1H, J=9), 6,79 (br s, 1H), 6,90 (m, 1H), 7,2 (m, 5H).
HRMS Beregnet for C21H25F3N202: 394,1868. Funnet: 394,1875. Analyse for C21H2SF3N202 • 2HC1:
Beregnet: C 53,97; H 5,82; N 6,00
Funnet: C 53,85; H 5,79; N 5,95.
Eksempel 73
( 2S. 3S)- 3-( 5- etyl- 2- metoksybenzylamino)- 2- fenylpiperidin-hydroklorid
<X>H NMR (fri base, CDC13) 5 1,16 (t, 3H, J=9) , 1,36 (m, 1H) , 1,57 (m, 1H), 1,88 (m, 1H), 2,12 (m, 1H), 2,48 (q, 2H), 2,76 (m, 2H), 3,24 (m, 1H), 3,38 (m, 4H), 3,60 (d, 1H, J=12), 3,86 (d, 1H, J=3), 6,57 (d, 1H, J=6), 6,74 (d, 1H, J=3), 6,92 (dd, 1H, J=3,6), 7,24 (m, 5H).
HRMS Beregnet for C21H28N20: 324,2202. Funnet: 324,2202.
Eksempel 74
( 2S, 3S)- 3-( 2- difluormetoksY- 5- nitrobenzylamino)- 2- fenylpiperidin- hydroklorid
<X>H NMR (fri base; CDC13) 6 1,50 (m, 1H) , 1,66 (m, 1H) , 1,98 (m, 2H), 2,82 (m, 2H), 3,28 (m, 1H), 3,42 (d, 1H, J=15), 3,64 (d, 1H, J=15), 3,95 (d, 1H, J=2), 6,30 (t, 1H, J=72), 7,08 (d, 1H, J=8), 7,30 (m, 5H), 8,04 (m, 2H).
FAB HRMS Beregnet for C19H21F2N303 (M+l): 378,1629. Funnet: 378,1597.
Eksempel 75
( 2S. 3S)- 3-( 2- difluormetoksy- 5- isopropylbenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. 245-247°C (dek.).
<X>H NMR (fri base; CDC13) 6 1,19 (2d, 6H, J=7) , 1,50 (m, 1H) , 1,75 (m, 2H) , 2,12 (m, 1H), 2,83 (m, 3H) , 3,25 (m, 1H) , 3,35 (d, 1H, J=14), 3,60 (d, 1H, J=14), 3,90 (d, 1H, J=3), 6,20 (t, 1H, J=75), 6,90 (m, 2H), 7,00 (m, 1H), 7,30 (m, 5H).
HRMS Beregnet for C22H28F2N20: 374,2170. Funnet: 374,2207. Analyse for C22H28F2N20- 2HC1 • 1/3H20 :
Beregnet: C 58,28; H 6,67; N 6,18
Funnet: C 58,17; H 6,52; N 6,17
Eksempel 76
( 2S. 3S)- 3-( 2- metoksy- 5- hydroksybenzylamino)- 2- fenylpiperidin-hydroklorid
Sm.p. 239-240°C (dek.).
<X>H NMR (fri base; CDC13) 6 1,42 (m, 1H) , 1,64 (m, 1H) , 1,90 (m, 1H) , 2,16 (m, 1H) , 2,82 (m, 2H), 3,26 (m, 1H), 3,36 (d, 1H, J=15), 3,42 (s, 3H), 3,58 (d, 1H, J=15), 3,92 (d, 1H, J=2) , 6,37 (d, 1H, J=2), 6,52 (m, 2H) , 7,26 (m, 5H) .
HRMS Beregnet for C19H24N202: 312,1836. Funnet: 312,1865.
Eksempel 77
( 2S. 3S)- 3-( 2- metoksy- 5- trifluormetoksybenzyl)- amino- 2- fenylpiperidin- hydroklorid
Sm.p. > 250°C.
<1>H NMR (fri base, CDC13) 3 1,36 (s, 1H) , 1,54 (m, 1H) , 1,86 (m, 1H), 2,06 (m, 1H), 2,76 (m, 2H), 3,22 (m, 1H), 3,32 (d, 1H, J=15), 3,48 (s, 3H), 3,58 (d, 1H, J=15), 3,85 (d, 1H, J=3), 6,57 (d, 1H, J=9), 6,80 (d, 1H, J=3), 6,92 (dd, 1H, J=3, 9), 7,22 (m, 5H).
HRMS Beregnet for C20H23F3N202 : 380,1711. Funnet: 380,1704. Analyse for C20H23F3N2O2 • 2HC1 • 0, 2H20:
Beregnet: C 52,57; H 5,60; N 6,13
Funnet: C 52,58; H 5,40; N 5,97.
Eksempel 78
( 2S. 3S)- 3-( 2- hydroksy- 5- trifluormetoksybenzylamino)-2-fenylpiperidin-hydroklorid
<X>H NMR (fri base; CDC13) 6 1,60 (m, 3H) , 2,04 (m, 1H) , 2,76 (m, 1H), 2,88 (m, 1H), 3,18 (m, 1H), 3,42 (s, 2H), 3,90 (m, 1H), 6,52 (m, 1H), 6,64 (d, 1H, J=9), 6,89 (m, 1H), 7,30 (m, 5H). HRMS Beregnet for C19H21F3N202: 366,1545. Funnet: 366,1562. Analyse for C19H21F3N202 • 2HC1 • l/3H20:
Beregnet: C 51,25; H 4,90; N 6,29
Funnet: C 51,30; H 4,75; N 6,22.
Eksempel 79
( 2S, 3S)- 3- f5- acetamido- 2-( 2. 2. 2- trifluoretoksy) benzylaminol - 2-fenylpiperidin- hydroklorid
Sm.p. > 270°C.
<1>H NMR (fri base; CDC13) 6 1,46 (m, 1H) , 1,82 (m, 1H) , 2,08 (m, 1H), 2,12 (s, 3H), 2,76 (m, 2H) , 3,20 (m, 1H), 3,48 (d, 1H, J=15), 3,58 (d, 1H, J=15) 3,82 (m, 1H), 4,08 (m, 2H), 6,44 (m, 1H), 6,58 (d, 1H, J=10), 6,78 (m, 1H), 7,26 (m, 5H), 7,58 (m, 1H) .
Eksempel 80
( 2S, 3S)- 3-( 2- difluormetoksy- 5- etylben2Ylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. 254-255°C.
<X>H NMR (fri base; CDC13) 5 1,12 (t, 3H, J=10) , 1,36 (m, 1H) , 1,44 (m, 1H), 1,82 (m, 1H), 2,10 (m, 1H), 2,48 (q, 2H, J=10), 2,8 (m, 1H), 3,10 (m, 1H), 3,34 (d, 1H, J=15), 3,58 (d, 1H, J=15), 3,9 (d, 1H, J=3), 6,12 (t, 1H, J=85), 6,78 (s, 1H), 6, 90 (m, 2H), 7,28 (m, 5H) .
Analyse for C21H26F2N20 • 2HC1:
Beregnet: C 58,19; H 6,51; N 6,47
Funnet: C 57,90; H 6,52; N 6,64.
Eksempel 81
( 2S. 3S)- 3-( 5- klor- 2- difluormetoksylbenzylamino)- 2- fenylpiperidin- hydroklorid
Sm.p. 272-274°C.
<X>H NMR (fri base; CDC13) 5 1,48 (m, 1H) , 1,64 (m, 1H) , 1,84 (m, 1H), 2,08 (m, 1H), 2,84 (m, 2H), 3,24 (m, 1H), 3,34 (d, 1H, J=15), 3,56 (d, 1H, J=15), 3,90 (d, 1H, J=3), 6,12 (t, 1H, J=70), 6,90 (d, 1H, J=10), 7,02 (m, 1H), 7,12 (m, 1H), 7,3 (m, 5H) .
Analyse for C19H21C1F2N20 • 2HC1 • l/3H20:
Beregnet: C 51,20; H 5,33; N 6,29
Funnet: C 51,03; H 5,32; N 6,30.
Eksempel 82
( 2S. 3S)- fenyl- 3-( 2- trifluormetoksybenzyl) amino- piperidin-hydroklorid
Sm.p. 231-233°C.
<X>H NMR (fri base, CDC13) 6 1,40 (m, 1H) , 1,60 (m, 1H) , 1,84 (m, 1H), 2,05 (m, 1H), 2,78 (m, 2H), 3,22 (m, 1H), 3,42 (d,•1H, J=15), 3,56 (d, 1H, J=15), 3,86 (d, 1H, J=3), 7,08 (m, 4H), 7,24 (m, 5H) .
Massespektrum: m/z 350 (moder). Analyse for C19H21F3N20 • 2HC1 • 0 , 25H20 : Beregnet: C 53,34; H 5,54; N 6,54. Funnet: C 53,19; H 5,40; N 6,54.
Claims (3)
1. Fremgangsmåte for fremstilling av en forbindelse med
formelen
hvor
R3 er H eller -CHj-R<1>, R<1> er aryl valgt fra indanyl, fenyl og naftyl; heteroaryl valgt fra tienyl, furyl, pyridyl og kino-lyl; og cykloalkyl med 3 til 7 karbonatomer, hvor et av karbonatomene eventuelt kan være erstattet av nitrogen, oksy-gen eller svovel; hvor hver av aryl- og heteroaryl-gruppene eventuelt kan være substituert med én eller flere substituenter, og (C3.7) -cyklo-alkylgruppen eventuelt kan være substituert med én eller to substituenter, idet substituentene uavhengig er valgt fra klor, fluor, brom, jod, nitro, (Ci.
10) alkyl eventuelt substituert med fra én til tre f luorgrupper, (ci-io) alkoksy eventuelt substituert med fra én til tre f luor-grupper, amino, (C^o) alkyl-S-,
(Ci.m) alkyl-SO- , (C^o) alkyl -S02- , fenyl, fenoksy, (Cj.^) alkyl - S02NH-, (d.10) alkyl-S02NH-(Ci.10) alkyl-, (C^o) alkylamino-di-(C:i-10) alkyl-, cyano, hydroksy, cykloalkoksy med 3 til 7 karbonatomer, (Ci.s) alkylamino, (C^J dialkylamino, HCONH- og { C^ g) - alkyl-CO-NH-, hvor nitrogenatomene i amino- og (C^) alkyl - amino-gruppene eventuelt kan være beskyttet med en passende beskyttelsesgruppe,- og R<2> er tienyl, benzhydryl, naftyl eller fenyl eventuelt substituert med fra én til tre substituenter uavhengig valgt fra klor, brom, fluor, jod, cykloalkoksy med 3 til 7 karbonatomer, (C^. 10) alkyl eventuelt substituert med fra én til tre f luor-grupper og (C^o) alkoksy eventuelt substituert med fra én til tre f luorgrupper, med det forbehold, når R3 er - CHj-R<1>, at enten er R<1> substituert med minst én av (Cx.10) alkyl substituert med én eller flere f luorgrupper eller ( C^. 10) alkoksy substituert med fra én til tre fluorgrupper, eller R<2> er substituert med minst én eller flere fluorgrupper, eller ( Cx. 10) alkoksy substituert med fra én til tre f luorgrupper, karakterisert ved reduksjon av en forbindelse med formelen
hvor R<2> er som angitt ovenfor, for å danne en forbindelse med formel I' hvor R<3> = H, dvs. en forbindelse med formelen
hvor R<2> er som angitt ovenfor,
og hvis man ønsker en forbindelse med formel I' hvor R3 er -CHj-R<1>, omsetning av forbindelsen (IV) med enten (a) en for-bin-delse med formelen R<1>COX, hvor R<1> er som angitt ovenfor og X er en utgående gruppe, fulgt av behandling av det resulterende amid med et reduksjonsmiddel, (b) en forbindelse med formelen R^HO, hvor R<1> er som angitt ovenfor, i nærvær av et reduksjonsmiddel, (c) en forbindelse med formelen R^HjX, hvor R<1> er som angitt ovenfor og X er en utgående gruppe, eller (d) en forbindelse med formelen R^-CHO, hvor R<1> er som angitt ovenfor, i nærvær av et tørremiddel eller ved anvendelse av et apparat som azeotropt fjerner det dannede vann, for å fremstille et imin med formelen
hvor Rx og R2 er som angitt ovenfor, og omsetning av iminet med et reduksjonsmiddel, fortrinnsvis natrium-triacetoksybor-hydrid.
2. Fremgangsmåte ifølge krav 1,
karakterisert ved at reduksjonen av forbindelsen med formel (II)utføres under anvendelse av natrium i en kokende alkohol eller under anvendelse av litiumaluminiumhydrid/aluminium-triklorid, eller reduksjonen er en elektrolytisk reduksjon.
3. Fremgangsmåte ifølge krav 1,
karakterisert ved at reduksjonen av forbindelsen med formel (II) utføres under anvendelse av hydrogen i nærvær av en metall-holdig katalysator, fortrinnsvis platina på karbon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67524491A | 1991-03-26 | 1991-03-26 | |
PCT/US1992/000065 WO1992017449A1 (en) | 1991-03-26 | 1992-01-14 | Stereoselective preparation of substituted piperidines |
Publications (4)
Publication Number | Publication Date |
---|---|
NO933413D0 NO933413D0 (no) | 1993-09-24 |
NO933413L NO933413L (no) | 1993-09-24 |
NO180484B true NO180484B (no) | 1997-01-20 |
NO180484C NO180484C (no) | 1997-04-30 |
Family
ID=24709639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO933413A NO180484C (no) | 1991-03-26 | 1993-09-24 | Fremgangsmåte for fremstilling av substituerte piperidiner |
Country Status (26)
Country | Link |
---|---|
US (1) | US5686615A (no) |
EP (1) | EP0581777A1 (no) |
JP (1) | JPH0794440B2 (no) |
KR (1) | KR0145432B1 (no) |
CN (1) | CN1038932C (no) |
AU (1) | AU647592B2 (no) |
BR (1) | BR9205807A (no) |
CA (1) | CA2106200C (no) |
CZ (3) | CZ293955B6 (no) |
EG (1) | EG19976A (no) |
FI (1) | FI106199B (no) |
HU (1) | HUT67276A (no) |
IE (1) | IE920939A1 (no) |
IL (2) | IL101328A (no) |
MX (1) | MX9201315A (no) |
MY (1) | MY110886A (no) |
NO (1) | NO180484C (no) |
NZ (1) | NZ242116A (no) |
PL (1) | PL169993B1 (no) |
PT (1) | PT100282A (no) |
RU (1) | RU2105001C1 (no) |
SK (2) | SK284565B6 (no) |
TW (1) | TW213900B (no) |
WO (1) | WO1992017449A1 (no) |
YU (1) | YU48260B (no) |
ZA (1) | ZA922164B (no) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
UA39168C2 (uk) * | 1991-06-20 | 2001-06-15 | Пфайзер, Інк. | Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі |
EP0533280B2 (en) | 1991-09-20 | 2004-12-01 | Glaxo Group Limited | Novel medical use for tachykinin antagonists |
ATE209186T1 (de) * | 1992-05-18 | 2001-12-15 | Pfizer | Überbrückte azabicyclische derivate als substanz p antagonisten |
JPH07506379A (ja) * | 1992-08-04 | 1995-07-13 | ファイザー・インコーポレーテッド | 物質p受容体アンタゴニストとしての3−ベンジルアミノ−2−フェニル−ピペリジン |
DE69331103T2 (de) * | 1992-08-19 | 2002-03-14 | Pfizer Inc., New York | Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen |
PT675886E (pt) * | 1992-12-10 | 2000-12-29 | Pfizer | Heterociclos nao aromaticos com substituintes aminometileno e sua utilizacao como antagonistas da substancia p |
US6369074B1 (en) * | 1992-12-10 | 2002-04-09 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
GB9305718D0 (en) * | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
US5294744A (en) * | 1993-04-20 | 1994-03-15 | Pfizer Inc. | Formylation process for aromatic aldehydes |
DE69404306T2 (de) | 1993-05-28 | 1997-10-30 | Pfizer | Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine |
US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Substance P antagonists for the treatment or prevention of sunburn. |
EP0659409A3 (en) * | 1993-11-23 | 1995-08-09 | Pfizer | Substance P antagonists for the inhibition of angiogenesis. |
EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
FR2728169A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
FR2728165A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
CA2216701A1 (en) * | 1995-03-27 | 1996-10-03 | Akira Okayama | Piperidine derivatives |
TW340842B (en) * | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
FR2741262B1 (fr) | 1995-11-20 | 1999-03-05 | Oreal | Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene |
EP0780375B1 (en) * | 1995-12-21 | 2002-09-11 | Pfizer Inc. | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists |
US6329396B1 (en) | 1996-06-10 | 2001-12-11 | Pfizer Inc. | Substituted benzylaminopiperidine compounds |
AU744261B2 (en) * | 1997-04-24 | 2002-02-21 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating eating disorders |
AU738047B2 (en) * | 1997-08-04 | 2001-09-06 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating mania |
WO1999007375A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating aggressive behaviour disorders |
GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
GB9716457D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
GB9816897D0 (en) * | 1998-08-04 | 1998-09-30 | Merck Sharp & Dohme | Therapeutic use |
RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
DE60007599T2 (de) * | 1999-10-18 | 2004-11-11 | Pfizer Products Inc., Groton | Verfahren zur Herstellung von zyklischen Piperidinylaminomethyl-trifluoromethyl-etherderivaten |
MXPA02004330A (es) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
IL142810A0 (en) * | 2000-05-03 | 2002-03-10 | Pfizer Prod Inc | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles |
WO2002004455A2 (en) | 2000-07-11 | 2002-01-17 | Albany Molecular Research, Inc | 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
NZ524673A (en) * | 2000-09-26 | 2005-08-26 | Tanabe Seiyaku Co | 5-phenylbenzylamine compounds, process for preparing the same and synthetic intermediates thereof |
WO2002028853A1 (fr) * | 2000-10-02 | 2002-04-11 | Tanabe Seiyaku Co., Ltd. | Compose de benzylamine, son procede de production et produit intermediaire correspondant |
US6911544B2 (en) | 2002-10-23 | 2005-06-28 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine |
CA2566920A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
RU2388751C2 (ru) | 2004-07-15 | 2010-05-10 | Амр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
KR101269568B1 (ko) * | 2005-07-04 | 2013-06-04 | 자난 사이텍 컴퍼니 리미티드 | 루테늄 착물 리간드, 루테늄 착물, 고정 루테늄 착물 촉매및 그의 제조방법과 용도 |
UA95454C2 (uk) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну |
EP1910292A1 (en) * | 2005-08-04 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Piperidine derivative as tachykinin receptor antagonist |
KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体 |
KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
EP2429293B1 (en) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
EP3587574B1 (en) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
WO2012027236A1 (en) | 2010-08-23 | 2012-03-01 | Schering Corporation | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
BR112015006990A2 (pt) | 2012-09-28 | 2017-07-04 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de pelo menos um composto |
PT2925888T (pt) | 2012-11-28 | 2017-12-13 | Merck Sharp & Dohme | Composições e métodos para tratamento do cancro |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
CN103204768A (zh) * | 2013-03-12 | 2013-07-17 | 西北大学 | 一种对羟基苯甲醛的合成方法 |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2020019247A1 (en) * | 2018-07-26 | 2020-01-30 | Xw Laboratories, Inc. | Compounds as neurokinin-1 receptor antagonists and uses thereof |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2355659A (en) * | 1939-12-15 | 1944-08-15 | Hoffmann La Roche | Piperidine derivatives and process for the manufacture of the same |
US4267318A (en) * | 1979-09-12 | 1981-05-12 | G. D. Searle & Co. | 1-(Diarylmethyl)-4-piperidinamine and derivatives thereof |
MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
PL168236B1 (pl) * | 1990-05-31 | 1996-01-31 | Pfizer | Sposób wytwarzania podstawionych piperydyn PL PL PL |
-
1992
- 1992-01-14 CZ CZ19973877A patent/CZ293955B6/cs not_active IP Right Cessation
- 1992-01-14 WO PCT/US1992/000065 patent/WO1992017449A1/en active IP Right Grant
- 1992-01-14 EP EP92905084A patent/EP0581777A1/en not_active Ceased
- 1992-01-14 KR KR1019930702889A patent/KR0145432B1/ko not_active IP Right Cessation
- 1992-01-14 RU RU93057733/04A patent/RU2105001C1/ru not_active IP Right Cessation
- 1992-01-14 AU AU12448/92A patent/AU647592B2/en not_active Ceased
- 1992-01-14 SK SK996-99A patent/SK284565B6/sk unknown
- 1992-01-14 SK SK3672-92A patent/SK284185B6/sk unknown
- 1992-01-14 CA CA002106200A patent/CA2106200C/en not_active Expired - Fee Related
- 1992-01-14 PL PL92301110A patent/PL169993B1/pl unknown
- 1992-01-14 CZ CZ19973876A patent/CZ293954B6/cs not_active IP Right Cessation
- 1992-01-14 CZ CS19923672A patent/CZ289960B6/cs not_active IP Right Cessation
- 1992-01-14 HU HU9302709A patent/HUT67276A/hu unknown
- 1992-01-14 JP JP4504747A patent/JPH0794440B2/ja not_active Expired - Fee Related
- 1992-01-14 BR BR9205807A patent/BR9205807A/pt not_active Application Discontinuation
- 1992-02-10 TW TW081100889A patent/TW213900B/zh active
- 1992-03-22 IL IL10132892A patent/IL101328A/xx not_active IP Right Cessation
- 1992-03-24 PT PT100282A patent/PT100282A/pt not_active Application Discontinuation
- 1992-03-24 MX MX9201315A patent/MX9201315A/es unknown
- 1992-03-25 ZA ZA922164A patent/ZA922164B/xx unknown
- 1992-03-25 NZ NZ242116A patent/NZ242116A/en unknown
- 1992-03-25 YU YU29892A patent/YU48260B/sh unknown
- 1992-03-25 IE IE093992A patent/IE920939A1/en not_active Application Discontinuation
- 1992-03-25 CN CN92102009A patent/CN1038932C/zh not_active Expired - Fee Related
- 1992-03-26 MY MYPI92000521A patent/MY110886A/en unknown
- 1992-03-26 EG EG16092A patent/EG19976A/xx active
-
1993
- 1993-09-20 US US08/119,149 patent/US5686615A/en not_active Expired - Fee Related
- 1993-09-24 FI FI934186A patent/FI106199B/fi active
- 1993-09-24 NO NO933413A patent/NO180484C/no not_active IP Right Cessation
-
2000
- 2000-06-26 IL IL13702100A patent/IL137021A0/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO180484B (no) | Fremgangsmåte for fremstilling av substituerte piperidiner | |
CZ390892A3 (en) | Fluoroalkoxybenzylamide derivatives of nitrogen-containing heterocycles | |
JP2002515486A (ja) | 掻痒性皮膚病の治療用の新規4−フェニルピペリジン | |
NO178187B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser | |
CZ189894A3 (en) | Bicyclic compounds containing nitrogen and pharmaceutical compositions containing thereof | |
JPH02223551A (ja) | 新規の▲n‐▼置換されたアザ複素環式カルボン酸類 | |
JPH0768214B2 (ja) | 神経安定性3−ピペリジノ−4−ヒドロキシクロマン誘導体 | |
RU2077531C1 (ru) | Способ получения замещенных (3-бензиламино)-2-фенилпиперидина, замещенные (3-бензиламино)-2-фенилпиридина и способ их получения | |
JP2889056B2 (ja) | メタノアントラセン化合物、該化合物を含有する精神病治療用医薬調剤および上記化合物の製造方法ならびに中間体 | |
CA1120036A (en) | 4-(naphthylmethyl)piperidine derivatives | |
CZ292947B6 (cs) | Způsob přípravy substituovaných piperidinů a nové meziprodukty tohoto postupu | |
WO1994027966A1 (en) | Process for preparing and resolving 2-phenyl-3-aminopiperidine | |
CA2072520A1 (en) | 2-(1-piperidyl) ethanol derivatives, their preparation and their therapeutic application | |
CZ296053B6 (cs) | 4-Substituované piperidiny | |
WO1981001407A1 (en) | Novel halophenyl-pyridyl-allylamine derivatives | |
JPH0533696B2 (no) | ||
EP0241292A2 (en) | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | |
JP2004525982A (ja) | Tnf活性を有するフェニル−およびピリジル−ピペリジン類 | |
US20140296528A1 (en) | 4-aryl-1-(biarylmethylene) piperidine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |